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ABSTRACT 
Modulation of Chondrogenic and Osteogenic 
Differentiation of Mesenchymal Stem Cells through 
Signals in the Extracellular Microenvironment 
by 
Jiehong Liao 
ii 
Damage to synovial joints results in osteochondral defects that only heal 
with inferior fibrous repair tissue. Since mesenchymal stem cells (MSCs) playa 
vital role in the natural development, maintenance, and repair of cartilage and 
bone, tissue engineering strategies to enhance functional regeneration by 
modulating MSC differentiation are a promising alternative to the limitations and 
potential complications associated with current conventional therapies. In this 
work, signals present in the native microenvironment were utilized in fabricating 
polymer/extracellular matrix composite scaffolds to guide chondrogenic and 
osteogenic differentiation. 
In an osteochondral defect environment, interactions exist between bone 
marrow cell populations. Although MSCs have been extensively utilized for their 
ability to support hematopoietic stem and progenitor cells (HSPCs), the role of 
HSPCs in regulating the osteogenic differentiation of MSCs in the bone marrow 
niche is not well understood, and thus was explored via direct contact co-culture. 
iii 
HSPCs in a low dose with sustained osteogenic induction by dexamethasone 
accelerated osteogenesis and enhanced mineral deposition, whereas the lack of 
induction signals affected the spatial distribution of cell populations and minerals. 
Thus, HSPCs presumably play an active role in modulating the development and 
maintenance of the osteogenic niche. 
Since physical signals affect cellular activity, flow perfusion culture was 
employed to deposit mineralized extracellular matrix (ECM) with different maturity 
and composition on electrospun poIY(E-caprolactone) (PCl) microfibers in 
fabricating mineralized PCLlECM composite scaffolds. The presence of 
mineralized matrix induced the osteogenic differentiation of MSCs even in the 
absence of dexamethasone, and a more mature matrix with higher quantities of 
collagen and minerals improved osteogenesis by accelerating alkaline 
phosphatase expression and matrix mineralization. 
To determine whether PCLlECM scaffolds can be applied to support the 
chondrogenic differentiation of MSCs, cartilaginous PCLlECM composite 
scaffolds were fabricated. The presence of cartilaginous matrix reduced 
fibroblastic phenotype and in combination with transforming growth factor-~1 
(TGF-~1), further promoted chondrogenesis as evident in elevated levels of 
glycosaminoglycan synthetic activity. While further investigation is necessary to 
optimize and test these scaffolds to induce the regeneration of cartilage and 
bone, this work demonstrates the importance of harnessing Signals present in the 
native microenvironment to modulate chondrogenic and osteogenic 
differentiation. 
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CHAPTER I 
OVERVIEW 
Conventional therapies to repair cartilage and bone defects involve donor 
grafts, which face challenges in their limited supply along with complications 
associated with donor site morbidity. With respect to cartilage, procedures to 
stimulate extrinsic repair typically result in inferior fibrocartilage that lacks the 
structure and composition required for long-term mechanical stability. Tissue 
engineering is a promising alternative where cells, bioactive factors, and 
scaffolds are incorporated to enhance tissue regeneration. Modulating the 
differentiation response of mesenchymal stem cells (MSCs) is a central concept 
in tissue engineering strategies since MSCs play a vital role in the natural 
development, maintenance, and repair of cartilage and bone. MSCs are 
influenced by signals present in the native microenvironment, and understanding 
these interactions to engineer key aspects of these signals ex vivo, enables the 
development of inductive scaffolds to facilitate the regeneration osteochondral 
tissue. 
The overall goal of this thesis work is to explore signals present in the 
native tissue microenvironment and utilize these interactions in fabricating 
polymer/extracellular matrix (PCLlECM) composite scaffolds to guide osteogenic 
and chondrogenic differentiation. This work addresses the following specific 
objectives: 
1. Examine the role of hematopoietic stem and progenitor cells in 
regulating the osteogenic differentiation of mesenchymal stem 
cells via cell-cell interactions in direct contact co-culture. 
2. Modulate the composition of mineralized PCUECM composite 
scaffolds through flow perfusion culture of osteoblastic cells and 
investigate how mineralized matrix maturity affects the 
osteogenic differentiation of mesenchymal stem cells in the 
absence of dexamethasone supplementation. 
3. Fabricate cartilaginous PCUECM composite scaffolds through 
flow perfusion culture of chondrocytes and evaluate the ability of 
cartilaginous matrix to support the chondrogenic differentiation 
of mesenchymal stem cells in combination with transforming 
growth factoH31. 
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This thesis begins with background information on the biology and repair 
of cartilage and bone, along with considerations for osteochondral tissue 
engineering. Following chapters present investigations into factors which 
modulate MSC differentiation in terms of cellular interactions in the bone marrow 
niche, in addition to mineralized matrix signals and cartilaginous matrix signals 
incorporated into a biodegradable scaffolding system. Concluding remarks 
summarize the major findings and provide perspective for future directions. 
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CHAPTER II 
BACKGROUND 
Biology of Cartilage and Bone 
Skeletal tissues function as the physical support system of the body. Both 
cartilage and bone serve vital roles in normal physiological activities, with 
complex biological mechanisms governing their development, maintenance, and 
repair. For successful strategies to facilitate the regeneration of diseased or 
damaged tissue, it is necessary to understand the biology of these complex 
tissues, from their macroscopic structure down to the extracellular composition 
and cellular interactions. 
Cartilage 
Articular cartilage is a specialized form of hyaline cartilage which provides 
a smooth lubricated covering on the articulating ends of bones in synovial joints. 
This lining of cartilage functions as a compressive load-bearing surface to evenly 
distribute forces onto bone and to reduce friction during joint movement. The 
shock-absorbing function of cartilage tissue is attributed to its hydrated nature 
and ordered structure, from the superficial zone which is the direct articulating 
surface, down to the calcified zone joining cartilage to bone. Articular cartilage is 
unique among connective tissues since it is only sparsely populated by cells 
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(chondrocytes) and lacks blood vessels, nerves, and lymphatics, making 
cartilage a tissue with low turnover and limited natural healing capacity. 
Articular cartilage is composed of both a fluid phase and a solid phase as 
a biphasic viscoelastic material with high resilience. Mature cartilage is 
approximately 70% water, 20% collagen, and 6% proteoglycans by weight, with 
the remainder consisting of non-collagenous proteins and other molecules [1]. 
The fluid phase of cartilage contributes to its hydrated and lubricating nature, 
where fluid flow and osmotic pressure are the mechanisms responsible for how 
cartilage is able to resist high mechanical loads [2]. The solid phase of cartilage 
consists of cells and extracellular matrix, which in large part is collagen type " 
and aggrecan, whose interactions impart both tensile and compressive properties 
to the cartilage matrix [3]. Articular cartilage has a zonal structure (superficial, 
middle, deep, and calcified zones), where the organization and composition of 
matrix components differ with depth from the articulating surface to the 
subchondral bone [4]. This zonal structure influences the biomechanical 
properties of cartilage and its resilience in repeated loading during joint 
movement. 
The only cells present in articular cartilage are chondrocytes, which have 
a rounded morphology, and make up less than 10% of the tissue volume [1]. 
Mature chondrocytes are responsible for the synthesis and maintenance of their 
surrounding cartilage matrix and rarely divide under normal conditions [5]. 
Although chondrocytes are embedded in large volumes of extracellular matrix, 
they respond to a variety of stimuli including growth factors, matrix molecules, 
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mechanical loads, and hydrostatic pressure changes [2]. Chondrocytes develop 
from chondroblasts, chondroprogenitor cells differentiated from mesenchymal 
stem cells in the bone marrow and synovium [6, 7]. Since cartilage tissue is 
avascular with such low cell density, chondrocytes obtain nutrients through 
diffusion from the synovial fluid as facilitated by fluid flow during joint movement 
[8]. 
While water is the most abundant component of articular cartilage, 
collagen is the main structural constituent of the cartilage matrix. Collagen type II 
is the principal collagen in cartilage which provides tensile strength [2]. The 
tensile properties of cartilage are attributed to the meshwork of collagen type II 
fibrils formed around a core of collagen type XI aggregates, where fibrillar 
diameter and crosslinking are modulated by collagen type IX [9, 10]. Aggrecan is 
the predominant proteoglycan in cartilage which provides compressive strength 
[10]. The compressive properties of cartilage are attributed to glycosaminoglycan 
(GAG) chains of chondroitin sulfate and keratan sulfate linked to the core protein 
of aggrecan, which are responsible for hydrophilic interactions and the osmotic 
swelling pressure in cartilage [11]. Aggrecan also joins with hyaluronan through 
link proteins to form proteoglycan aggregates, further enforcing the compressive 
nature of cartilage [12, 13]. Other proteoglycans in cartilage, such as decorin and 
fibromodulin, modulate collagen fibril formation and sequester growth factors [4]. 
Non-collagenous proteins in cartilage, such as cartilage oligomeric matrix protein 
(CaMP) and fibronectin, are involved in matrix-matrix and cell-matrix interactions 
and signaling [14]. 
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Damage to articular cartilage may result from impact or torsional joint 
injuries, repetitive loading, or degenerative diseases such as osteoarthritis, 
where cartilage tissue deteriorates leaving areas of exposed bone. Cartilage has 
a limited capacity for regeneration as compared to bone, due to its low cellularity 
and restricted access to stem and progenitor cells. Depending on the severity of 
damage, cartilage lesions range in depth and thus healing response [15, 16]. 
Chondral lesions are fissures or tears confined to the cartilage layer which results 
in intrinsic repair, relying on chondrocytes to proliferate and synthesize 
extracellular matrix. However, since chondrocytes only increase their synthetic 
activity as a transient response to injury, chondral lesions do not heal and thus, 
leave permanent defects that propagate with progressive loss and deterioration 
of the cartilage matrix [13, 17, 18]. Osteochondral lesions penetrate down to the 
subchondral bone layer which results in an extrinsic repair, beginning with an 
inflammatory response and fibrin clot formation, then the recruitment, 
proliferation, and chondrogenic differentiation of mesenchymal cells, and finally 
the synthesis of extracellular matrix [18-21]. This extrinsic wound healing 
response results in the formation of new cartilage tissue that is fibrous in nature 
and lacks the structure and composition required for long-term mechanical 
stability [22]. Among the factors involved in cartilage repair, transforming growth 
factors (TGF-~) modulate the chondrogenic differentiation of mesenchymal cells, 
while insulin-like growth factors (IGF) and bone morphogenetic proteins (BMP) 
maintain the differentiated phenotype of chondrocytes and stimulate the 
production of collagen and proteoglycans [18]. 
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Since cartilage tissue itself has a limited capacity for regeneration, 
conventional procedures to repair cartilage defects include resurfacing 
techniques and the transplantation of cartilage grafts or chondrocytes [23]. 
Resurfacing methods aim to access bone marrow and initiate extrinsic repair by 
penetrating the subchondral bone layer via abrasion, microfracture, or drilling 
[24-26]. These methods yield fibrous repair tissue with variable composition, 
eventually resulting in the formation of fibrocartilage which lacks durability [26-
28]. Autologous procedures include the transplantation of cartilage plugs 
(MosaicPlasty) since mature cartilage tissue consists of the appropriate structure 
and composition, and also the implantation of chondrocytes (Autologous 
Chondrocyte Implantation (ACI» since differentiated cells in mature cartilage 
tissue exhibit the appropriate chondrocyte phenotype [29, 30]. Challenges in the 
use of autologous tissue for cartilage repair include the limited availability of 
donor tissue and consequent donor site morbidity from the harvest of healthy 
cartilage. Although allogenic sources have been explored for cartilage repair, 
transplantation of allogenic tissue often results in an immune response, even in 
the immunologically privileged joint environment [31, 32]. In either case, joint 
inflammation following these procedures is commonly associated with poor 
integration and mechanical mismatch between the donor and host tissue [33]. 
Bone 
Bone is the rigid support structure of the body which protects internal 
organs and provides the framework for load-bearing and motion. The mineralized 
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nature of bone, with both compact structure in cortical bone, and porous 
trabecular structure in cancellous bone, allows the transfer of mechanical forces 
during movement. Bone serves as a reservoir of calcium salts and other minerals 
that are important for metabolism, and the medullary cavity of long bones is the 
site where blood and immune cells are generated in the bone marrow. With its 
vascularized nature and diverse population of cells (osteoblasts, osteocytes, 
osteoclasts), bone is a dynamic tissue that is constantly remodeled. 
Bone is composed of both an organic phase and a mineral phase as a 
composite material that possesses both flexibility and strength. Mature bone is 
approximately 20% water, 35% organic molecules, and 45% minerals by weight 
[34]. The organic phase of bone consists of cells and extracellular matrix, which 
in large part is collagen type I, with a fibrous structure for elasticity [35, 36]. The 
hard mineral phase of bone consists of hydroxyapatite that has a calcium 
phosphate crystal structure for strength [36-38]. The mechanical properties of 
bone vary with shape and structure (long, short, flat, irregular, or seasmoid) [34]. 
Depending on the primary mechanism of bone formation, bone has either a 
woven or lamellar structure. Woven bone is deposited during rapid 
intramembranous bone formation directly within a mesenchymal cell 
condensation, or endochondral bone formation through a cartilage intermediate, 
where collagen bundles are randomly oriented, then later remodeled to lamellar 
bone [34]. Lamellar bone is deposited during slow appositional bone formation on 
surfaces of cartilage or bone, where collagen bundles are ordered to form regular 
sheets [34]. The structural arrangement, along with matrix interactions, 
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influences the biomechanical properties of bone as a load-bearing tissue and its 
ability to adapt to physiological conditions through remodeling. 
The three types of bone cells in bone tissue are osteoblasts, osteocytes, 
and osteoclasts, each with specialized functions in bone remodeling. Osteoblasts 
are bone-forming cells that produce extracellular matrix and secrete factors to 
control mineralization. Osteocytes are terminally differentiated osteoblasts which 
become entrapped in bone matrix, and with long cytoplasmic processes, act as 
mechanoreceptors to coordinate cellular response to mechanical signals in the 
dense bone tissue [39]. Osteoclasts are large multinucleated bone-resorbing 
cells that break down bone matrix by secreting hydrogen ions and hydrolytic 
enzymes to dissolve minerals and digest matrix proteins [40]. Whereas 
osteoclasts develop from monocytes/macrophages differentiated from 
hematopoietic stem cells in the bone marrow, osteoblasts and osteocytes 
develop from osteoprogenitor cells differentiated from mesenchymal stem cells in 
the bone marrow and periosteum [41]. Since bone tissue has such a dense 
structure, bone cells obtain nutrients through diffusion from a network of vascular 
canals from the bone marrow [34]. 
Collagen is the major constituent of the organic phase in bone matrix, 
making up approximately 90% of the organic component in bone, with the 
remainder consisting of non-collagenous proteins, proteoglycans, and other 
molecules [34]. Collagen type I is the principal collagen in bone, and as a fibril-
forming collagen, post-translationally modified collagen type I chains contain 
hydroxyproline and hydroxylysine residues that allow for crosslinking to form 
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stable fibers [42, 43]. In much lower quantities, bone also contains collagen types 
III, V, and XII, which are responsible for controlling collagen type I fibril formation 
and bundling [35]. Small leucine-rich proteoglycans (SLRPs), such as biglycan 
and lumican, the most abundant proteoglycans in bone matrix, are also involved 
in the structural organization of bone and play an essential role in regulating 
growth factor activity [44]. Together, collagen type I fibrils provide bone its elastic 
properties and act as a template for the deposition and alignment of mineral 
crystals, while the process of mineralization is facilitated by non-collagenous 
proteins, such as osteocalcin or bone gla protein (BGP), bone sialoprotein (BSP), 
and bone morphogenetic protein (BMP) [34, 35]. The mineral phase in bone 
matrix, that gives bone its hardness, is composed of crystalline hydroxyapatite 
(Ca1O(P04)6(OHh) made of calcium and phosphate [37]. The process of 
mineralization in bone is the heterogeneous nucleation of crystals on the 
collagen type I matrix. Enzymes secreted by bone cells neutralize inhibitors of 
mineralization, while anionic non-collagenous proteins act as nucleators of initial 
apatite formation. As mineral crystals agglomerate and grow, crystal size and 
shape are regulated by matrix proteins [35]. Alkaline phosphatase plays an 
important role in this process of mineralization as an enzyme that hydrolyzes 
organic phosphate and calcium substrates to create a supersaturated 
microenvironment where calcium and phosphate ions are readily available for 
incorporation into the developing bone matrix [45]. 
Damage to bone tissue may result from impact injury or degenerative 
diseases such as osteoporosis, where bone is fragile and susceptible to fracture 
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due to low bone mass. Surgical resection of bone tumors or traumatic injury 
typically results in the loss of large regions of bone, creating critical-sized defects 
or non-unions that do not heal. Depending on the severity of damage, bone 
tissue may regenerate at various rates or fail to heal at all, and thus require 
interventions to enhance or facilitate the process of regeneration. Nevertheless, 
since bone is a vascularized tissue with access to progenitor cells in the marrow 
and has the capacity for remodeling, regeneration to restore full form and 
function occurs more readily than for cartilage. The process of bone fracture 
healing consists of an inflammatory response, leading to the recruitment, 
proliferation, and osteochondral differentiation of mesenchymal cells responsible 
for initiating the reparative phase, where woven bone is formed through 
intramembranous and endochondral ossification, that is finally remodeled to 
lamellar bone architecture with mechanical strength [46, 47]. Aside from the initial 
inflammatory factors, bone morphogenetic proteins (BMP) modulate the 
osteogenic differentiation of mesenchymal cells, while transforming growth 
factors (TGF-~), insulin-like growth factors (IGF), and fibroblast growth factors 
(FGF) stimulate the proliferation and synthetic activity of differentiated bone cells 
[48,49]. 
Although the natural process of bone regeneration is sufficient to heal 
most fractures, larger defects require surgical procedures to enhance or facilitate 
bone regeneration. Conventional methods to repair bone defects involve the 
transplantation of bone grafts in the form of autologous bone chips or blocks 
harvested from healthy bone tissue, since bone matrix itself is both 
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osteoinductive and osteoconductive [50-52]. While autografts have a high 
success rate due to the capacity of bone cells to remodel the transplanted bone 
matrix, harvesting bone tissue results in donor site morbidity [53, 54]. Allografts 
are alternative options for significant bone repair, but potential complications 
such as inflammation due to immune response and the risk of infection or 
disease transmission, limit their application [55, 56]. 
Stem Cells 
Stem cells have the ability of self-renewal to retain stemness and the 
capacity for differentiation into specialized cell types in the body. Adult stem cells 
are responsible for the maintenance and regeneration of damaged or diseased 
tissue. Although the presence of adult stem cells have been confirmed in most 
differentiated tissues, bone marrow contains the most prominent stem cell 
compartment, and is the site where both hematopoietic stem cells and 
mesenchymal stem cells were first discovered [57, 58]. 
Stem cells in the bone marrow niche possess the capacity to differentiate 
into multiple cell types. Even though the stem cell population is very rare, as only 
1 in 10,000 to 15,000 cells in the bone marrow is considered a stem cell, the 
stem cell niche contains signals which affect stem cell self-renewal [59]. In order 
to maintain a pool of progenitor cells, the process of self-renewal relies on the 
balance between symmetric and asymmetric cell division. This allows the 
proliferation of differentiated specialized cells while still maintaining a pool of 
undifferentiated stem cells. Understanding stem cell characteristics and 
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interactions are essential in utilizing this therapeutic cell source for clinical 
applications. 
Mesenchymal Stem Cells 
Mesenchymal stem cells (MSCs) or marrow stromal cells are 
characterized by their capacity to differentiate into multiple mesodermal lineages, 
such as cartilage and bone, and also by their ability to support hematopoietic 
cells even after their differentiation into osteoblasts [60, 61]. MSCs are 
multipotent progenitors that are not tissue-specific, in that they reside in multiple 
sites besides bone marrow. MSCs can be efficiently harvested from bone marrow 
aspirates, identified based on their adhesive properties to tissue culture plastic, 
isolated via colony formation when propagated in culture, and thus have been 
considered a heterogeneous population of stromal cells [62, 63]. MSCs playa 
vital role in the natural development, maintenance, and repair of cartilage and 
bone, and are often targeted in strategies to enhance tissue regeneration. 
Chondrogenic and osteogenic differentiation of MSCs are influenced by a broad 
range of signals, especially those present in the native microenvironment. The 
relationship between MSCs to both the structural and mechanical environment in 
which they are exposed, is an important aspect in modulating cellular response 
for tissue engineering applications. 
Chondrogenic differentiation of MSCs in vitro is typically initiated by three-
dimensional aggregation in high-density culture to maximize cell-cell gap-
junctions based on the process of condensation during development, or by three-
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dimensional low-density culture to mimic post-condensation where extracellular 
matrix molecules accumulate in the pericellular environment [64, 65]. 
Chondrogenic induction can be further stimulated by growth factors such as 
transforming growth factors (TGF-I3), though ascorbic acid is essential for the 
organization and maturation of the collagen extracellular matrix, and 
contributions or interactions of other bioactive factors are commonly studied 
under serum-free culture conditions [66]. Chondrocyte development progresses 
through sequential stages consisting of proliferation, differentiation and 
extracellular matrix synthesis, and hypertrophy [67]. As MSCs undergo 
chondrogenic differentiation, Sox-9 expression is detected at the onset of 
differentiation, collagen type I expression decreases while collagen type II and 
aggrecan increase as cartilage matrix is generated, and collagen type X 
expression increases when chondrocytes become hypertrophic [68]. The end 
result in terms of tissue formation is a cartilaginous extracellular matrix 
predominantly consisting of collagen type II and glycosaminoglycan which can be 
directly quantified in vitro. 
Osteogenic differentiation of MSCs in vitro is typically induced by the 
glucocorticoid dexamethasone or growth factors such as bone morphogenetic 
proteins (BMP), while osteoblastic progression and the formation of mineral 
nodules is dependent on ascorbic acid and l3-glycerophosphate [69, 70]. 
Osteoblast development progresses through sequential stages consisting of 
proliferation, extracellular matrix synthesis and maturation, and mineralization 
[71]. As MSCs undergo osteogenic differentiation, collagen type I expression 
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decreases, whereas alkaline phosphatase (ALP) initially increases then 
decreases as mineralization is in progress [71-74]. Osteopontin (OPN) 
expression peaks during proliferation then again at the onset of differentiation, 
but prior to bone sialoprotein (SSP) which appears in differentiated osteoblasts 
and osteocalcin (OCN) which is associated with osteoblasts undergoing active 
mineralization [71-74]. The end result in terms of tissue formation is a 
mineralized extracellular matrix predominantly consisting of collagen type I and 
calcium phosphate which can be directly quantified in vitro. 
Hematopoietic Stem Cells 
Hematopoietic stem cells (HSCs) are characterized by their capacity to 
differentiate into myeloid and lymphoid lineages and also by their ability to 
generate all the blood and immune cells in the body [75]. HSCs are pluripotent 
progenitors that reside mainly in the bone marrow compartment, and while they 
can be activated to enter into circulation, they quickly return to their bone marrow 
niche or undergo differentiation. HSCs can be efficiently harvested from bone 
marrow aspirates, identified by their cell surface antigens, and isolated via 
immunoselection for combinations of receptors which have been confirmed to 
yield highly enriched cell populations capable of repopulating bone marrow [76, 
77]. Due to the therapeutic nature of HSCs in regenerating blood and immune 
cells, bone marrow transplantation is a routine procedure, although engrafiment 
and repopulation potential are directly related to the number of HSCs 
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transplanted [78]. Thus, ex vivo expansion of HSCs while maintaining their self-
renewal and differentiation capacity has significant clinical implications. 
Unlike MSCs, HSCs are non-adherent cells that require feeder layers of 
stromal cells and growth factors to remain viable and retain their stem cell 
characteristics once removed from the bone marrow niche environment [75]. 
Consequently, cell-cell interactions and soluble signals not only guide stem cell 
function but are essential for survival. However, it is unclear whether cell-matrix 
interactions with extracellular matrix components are sufficient for stem cell 
maintenance. Understanding the complexity of the bone marrow niche and 
engineering key aspects of these signals ex vivo would allow the maintenance of 
HSCs in vitro and enable the identification of factors involved in HSC expansion 
to further their therapeutic application. Since the bone marrow niche is a complex 
environment containing a heterogeneous population of cells, among which MSCs 
and osteogenic cells are responsible for generating mineralized extracellular 
matrix, it is important to consider how the cell-cell and cell-matrix interactions that 
take place within the niche regulate its development and maintenance. 
Tissue Engineering 
Tissue engineering of osteochondral tissue involves the incorporation of 
cells, bioactive factors, and scaffolds to either fabricate tissue constructs in vitro 
for implantation, or as means to enhance or facilitate tissue regeneration in vivo. 
The direct microenvironment in which a cell is exposed to plays a vital role in 
controlling cell function whether in vitro or in vivo, and thus must be taken into 
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careful consideration during the tissue engineering process. As cells interact with 
various components in their extracellular microenvironment, these factors in turn 
guide cellular response. Particularly in cartilage and bone, changes in the tissue 
microenvironment provide cues for regeneration remodeling. Understanding the 
key components in the native microenvironment and how those factors influence 
cellular function, provides the basis for which to engineer specific interactions in 
vitro to modulate cellular behavior or to design systems that induce tissue 
regeneration in vivo. 
Scaffolds 
Scaffolds for tissue engineering applications act as temporary structural 
supports, provide a template for cell growth and extracellular matrix deposition, 
and may be used as carriers for the delivery of cells or bioactive factors [79]. 
Scaffolding materials should be biodegradable, maintaining sufficient mechanical 
properties for temporary support during active tissue regeneration then 
completely degrading to restore native structure and function. Scaffolding 
materials and their degradation products must be biocompatible in that they must 
not be cytotoxic or immunogenic and must not cause unresolved inflammation. 
Scaffolds should be porous or degrade to provide porosity, with an 
interconnected pore structure allowing cellular infiltration, attachment, migration, 
and creating sufficient volume for tissue growth and integration. Natural and 
synthetic biomaterials are frequently employed in osteochondral tissue 
engineering since they fulfill many of these criteria or can be tailored accordingly. 
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Natural matrices are scaffolds consisting of purified extracellular matrix 
components such as collagen type II or hyaluronan for cartilage and collagen 
type I or hydroxyapatite for bone [80-83]. Although these natural scaffolds have 
shown promising results due to their role in native tissue, they can be easily 
degraded or resorbed in the physiological environment upon implantation. These 
materials also exhibit low mechanical properties since they are isolated 
components which lack the structural organization and necessary interactions as 
present in the native extracellular matrix from which they were derived. Thus, 
synthetic materials have been investigated for tissue engineering applications 
due to their ease of synthesis and processing to tailor material properties and 
degradation kinetics. 
Synthetic polymer scaffolds may be injectable for photo polymerization or 
chemical polymerization in situ, or prefabricated with a fixed architecture for 
implantation. Injectable systems for cartilage such as oligo(poly(ethylene glycol) 
fumarate) (OPF), has been investigated for the delivery of growth factors and 
cells in an osteochondral defect [84]. Injectable systems for bone such as 
poly(propylene fumarate) (PPF), has been investigated with the incorporation of 
carbon nanostructures for mechanical reinforcement [85]. Porous preformed 
scaffolds are typically fabricated through processing techniques such as rapid 
prototyping, salt leaching, emulsion templating, and electrospinning [86, 87]. 
Common polymers used for cartilage and bone tissue engineering include 
poly(lactic acid) (PLA) and poly(glycolic acid) (PGA) which have been approved 
by the Food and Drug Administration (FDA) for certain applications. The 
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copolymer poly(lactic-co-glycolic acid) (PlGA), where the ratio of PLA to PGA 
can be adjusted to control degradation and material properties, has been 
investigated as an electrospun nanofiber scaffold to support both the 
chondrogenic and osteogenic differentiation of MSCs [88]. These poly(a-hydroxy 
esters) all undergo bulk degradation through hydrolytic cleavage of ester bonds, 
resulting in lactic acid and glycolic acid which are natural metabolites that can be 
physiologically integrated into metabolic pathways. Depending on the 
degradation rate, the accumulation of acidic degradation products may result in a 
local inflammatory response [89, 90]. 
Poly(£-caprolactone) (PCl) is another FDA approved poly(a-hydroxy 
ester) that has been investigated for cartilage and bone tissue engineering, which 
has a slower degradation rate on the order of two years [91]. Since PCl also 
degrades through bulk hydrolysis, degradation rate depends on scaffold 
structure, particularly the surface to volume ratio. Maximizing surface area 
increases polymer contact with the aqueous environment and consequently 
accelerates degradation. PCl has been electrospun into highly porous nonwoven 
fiber mesh scaffolds which have been shown to support the differentiation of 
mesenchymal stem cells into cartilage and bone [92, 93]. 
Electrospinning 
Electrospinning is a technique used to create nonwoven fiber mesh 
scaffolds with high interconnected porosity, large surface to volume ratios, and 
adjustable fiber diameters. Polymer fibers can be electrospun with diameters 
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from the micro to nanoscale with porosities as high as 90% [93, 94]. 
Electrospinning has been applied to produce tissue engineering scaffolds using 
both natural and synthetic polymers to mimic the fibrous microenvironment in 
connective tissues. These scaffolds offer three-dimensional fibers for cell 
attachment and migration, along with accessible volume for cell infiltration and 
tissue integration. 
Electrospinning uses a simple and inexpensive setup typically consisting 
of a syringe pump, voltage source, and collector [95]. During the electrospinning 
process, a polymer solution is held at the needle tip by surface tension. When an 
electric field is applied via the voltage source, repulsive charges are induced 
within the polymer solution. This electrostatic force opposes the surface tension 
holding the polymer solution at the needle tip. When this electrostatic force 
overcomes the surface tension, a thin jet is formed and pulled toward the 
collector. As the jet of polymer solution travels the distance to the collector, the 
solvent evaporates leaving a continuous polymer fiber that can be captured on 
the collector. Both natural and synthetic polymers have been successfully 
electrospun for tissue engineering applications such as collagen, silk, PlGA, and 
pel [96, 97]. 
The main factors which affect electrospinning include solution properties, 
processing variables, and ambient conditions [95]. Solution properties are 
characterized by viscosity or polymer concentration, conductivity or solution 
charge density, surface tension, polymer molecular weight, and dipole moment 
and dielectric constant. Processing variables include flow rate, electric field 
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strength or voltage, distance between the needle tip and collector, needle tip 
design and placement, and collector composition and geometry. Ambient 
conditions that affect electrospinning are temperature, humidity, and air flow. Of 
these factors, fiber diameter and morphology is most dependent upon viscosity 
as adjusted via polymer concentration in solution. Fiber diameters increase with 
higher polymer concentration, and increasing viscosity also reduces the 
appearance of beads or junctions caused by solvent that has not completely 
evaporated for more uniform fiber morphology [98, 99]. Electric field strength is 
another important factor controlling fiber diameter and morphology. If the applied 
voltage is low but sufficient to overcome the surface tension in the droplet 
suspended at the needle tip, then a single continuous jet is formed. As the 
applied voltage is increased, the droplet recedes and a larger jet is formed that 
has been shown to splay into several jets causing inconsistent fiber diameters 
and the presence of beads [100]. The architecture of electrospun scaffolds can 
also be tailored by employing various methods of fiber collection, such as aligned 
fibers using a rotating cylindrical drum collector rather than a stationary target. 
Aligned fibers affect cell orientation and matrix production and have been applied 
to model the superficial zone of articular cartilage [101, 102]. 
Electrospun PCl nanofiber scaffolds support the chondrogenic and 
osteogenic induction of MSCs when cultured with bioactive factors in vitro and 
have shown promising results when implanted as a construct in vivo [103-106]. 
Not only do electrospun fiber scaffolds mimic the structural features of the 
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extracellular matrix, with modifications such as surface coatings, these scaffolds 
can be engineered to provide cells with biological signals. 
Bioreactors 
Bioreactors in tissue engineering are designed to establish uniform 
distributions of cells seeded onto a scaffold, facilitate mass transfer to and from 
cells within a construct, and provide physiologically relevant mechanical signals 
[107]. The later is based on the concept that the formation of functional tissue 
can be enhanced by replicating the mechanical environment of the native tissue. 
Since articular cartilage formation and endochondral bone formation exists in a 
fluid environment, joint movement imparts mechanical forces, mainly hydrostatic 
and direct compression, along with shear and some instances of tension. These 
forces are positive stimuli for osteochondral differentiation and extracellular 
matrix synthesis [108]. 
The two main types of mechanical stimulation most commonly 
investigated to produce osteochondral tissue of functional quality include 
hydrostatic compression and direct compression. Hydrostatic compression 
occurs during joint movement as a result of synovial fluid pressure in the joint 
capsule. Direct compression occurs when the joint surface is directly compressed 
by the opposing joint. Bioreactors designed to apply physiological loading and 
investigations into the magnitude, frequency, and duration of loading have 
generally shown enhanced matrix synthesis with dynamic stimulation as opposed 
to constant pressure [109-112]. 
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Three-dimensional constructs for tissue engineering require the delivery of 
oxygen and nutrients to the interior of the construct for cell growth and tissue 
formation. In conventional static culture, where constructs are maintained 
statically in culture dishes, both internal and external mass transfer is through 
passive diffusion from the surrounding culture medium, which has detrimental 
effects on cell survival and limit culture duration [113, 114]. In basic dynamic 
culture, constructs are maintained with convective mixing of culture medium to 
improve external mass transfer through the surrounding fluid flow and convection 
over the surfaces of the constructs. Such bioreactors include spinner flasks with 
turbulent flow that often results in the formation of a fibrous capsule around the 
construct, and rotating vessels with laminar flow and thus improved peripheral 
tissue with no fibrous capsule formation [114-116]. Perfusion bioreactors 
enhance both internal and external mass transport by the flow of culture medium 
through the interconnected pores of the construct, thereby improving the delivery 
of oxygen and nutrients to the cells within the construct. In order to ensure that 
fluid flows through and not around the construct, there must be a tight fit between 
the construct and the walls of the flow chamber. Although constructs cultured in 
perfusion bioreactors do not show fibrous capsule formation, non-uniform tissue 
growth may result due to the unilateral direction of flow causing cells to deposit 
matrix with more collagen type I at the top surface of the construct in response to 
more direct fluid shear of higher magnitude [117]. The fluid flow rate can be 
optimized for tissue growth where lower flow rates may yield more uniform tissue. 
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Osteochondral tissues experience fluid shear stresses in the physiological 
environment, as mechanical loading creates fluid flow in the hydrated matrix of 
cartilage or through the canaliculus microstructure of bone. Fluid shear stresses 
have been shown to promote both chondroblast and osteoblast phenotype and 
enhance extracellular matrix deposition [118, 119]. The interconnected porosity 
of a scaffold creates channels for fluid flow, and cells attached at the walls of 
these channels experience shear forces directly associated with the rate of fluid 
flow. These channels can be modeled as cylindrical conduits to calculate the 
relationship between volumetric flow rate and shear stress at the wall [120]. As 
cells deposit increasing amounts of extracellular matrix that accumulates in the 
pore volume, the diameter of the channels or conduits decrease, and therefore 
results in higher fluid shear stresses over extended culture periods. 
The perfusion bioreactor system developed in our laboratory provides 
direct fluid flow perfusion through tightly press-fitted constructs placed within 
individual flow chambers (Figure 11-1) [121]. This bioreactor consists of a block 
with six chambers in which a cassette containing the press-fitted scaffold is 
placed within each chamber. The chambers are sealed with screw tops and 
connected to an inflow and an outflow medium reservoir via silicone tubing to 
allow oxygen diffusion. Medium is circulated through the closed system using a 
peristaltic pump and complete medium changes can be performed periodically to 
replenish nutrients. Studies in using this perfusion bioreactor have largely been 
conducted to investigate the osteogenic differentiation of MSCs on titanium fiber 
mesh scaffolds and starch-based fiber mesh scaffolds with promising results 
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[119, 122]. Thus efforts are warranted towards the transition to a biodegradable 
scaffolding system with the capacity to modulate both osteogenic and 
chondrogenic differentiation of MSCs for osteochondral tissue engineering 
applications. This thesis work begins with examining cellular interactions that 
regulate osteogenic differentiation specifically within the bone marrow niche 
microenvironment, and then explores mineralized extracellular matrix signals 
incorporated into a biodegradable scaffolding system in modulating 
osteogenesis, and finally applying the scaffolding system to investigate 
chondrogenesis through cartilaginous extracellular matrix signals. 
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Figure 11-1: Schematic diagram and photograph of the flow perfusion bioreactor. 
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CHAPTER III 
INVESTIGATING THE ROLE OF HEMATOPOIETIC STEM AND 
PROGENITOR CELLS IN REGULATING THE OSTEOGENIC 
DIFFERENTIATION OF MESENCHYMAL STEM CELLS IN VITRO t 
Abstract 
Significant progress has been made in understanding the hematopoietic 
supportive capacity of both mesenchymal stem cells (MSCs) and osteogenic 
cells in maintaining hematopoietic stem and progenitor cells (HSPCs) in vitro. 
However the role of HSPCs in regulating their bone marrow niche environment 
through influencing the function of neighboring cell populations to complete this 
reciprocal relationship is not well understood. In this study, we investigated the 
influence of HSPCs on the osteogenic differentiation of MSCs in vitro, using a 
highly enriched population of hematopoietic cells with the phenotype c-Kit+ Sca-
1 + Lineage- (KSL) and bone marrow derived mesenchymal stromal cells in direct 
contact co-culture in medium with or without the addition of the osteogenic 
supplement dexamethasone. The data suggest that a low dose of HSPCs in co-
culture with MSCs accelerates the osteogenic progression of MSCs as evidence 
in the reduced cellularity, earlier peak in alkaline phosphatase activity, and 
t This chapter was submitted to the Journal of Orthopedic Research as: Liao J, Hammerick KH, 
Challen GA, Goodell MA, Kasper FK, Mikos AG. Investigating the role of hematopoietic stem and 
progenitor cells in regulating the osteogenic differentiation of mesenchymal stem cells in vitro. 
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enhanced calcium deposition compared to cultures of MSCs alone. We found 
that it is the primitive hematopoietic stem and progenitor cells in the population 
treated with dexamethasone that are responsible for augmenting the osteogenic 
differentiation of MSCs. Therefore, our findings further support the concept that 
HSPCs are actively involved in regulating the development and maintenance of 
the stem cell niche environment in which they reside. 
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Introduction 
Hematopoietic stem and progenitor cells (HSPCs) have the capacity of 
self-renewal and are able to generate blood and immune cells to repopulate the 
bone marrow. However, unlike mesenchymal stem cells (MSCs), hematopoietic 
cells are difficult to expand in vitro. Since HSPCs function in a bone marrow 
microenvironment and reside near the endosteal surface of trabecular bone, 
recreating this stem cell niche in vitro may enable the expansion of functional 
hematopoietic cells ex vivo. To effectively engineer the marrow 
microenvironment, it is essential to understand the interactions between resident 
cell populations, as intimate contact between supporting cells, growth factors, 
and extracellular matrix cues provide a specific microenvironment that balances 
stem cell self-renewal versus differentiation and quiescence versus proliferation. 
The cellular components comprising the stem cell niche contain a heterogeneous 
population of cells, and in addition to hematopoietic progenitors, include 
multipotent mesenchymal progenitor cells and osteoblastic cells that may play an 
integral role within the stem cell niche. While significant progress has been made 
in understanding the hematopoietic supportive capacity of both MSCs and 
osteogenic cells [123-126], little is known about the ability of HSPCs to regulate 
the development and maintenance of their own niche environment by influencing 
neighboring cells. Since hematopoietic cells and mesenchymal populations 
reside in such close proximity, it is widely believed that there is substantial 
crosstalk between HSPCs and the other cellular components of the niche [127-
129]. 
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HSPCs and their primitive progeny are primarily located proximal to the 
endosteal surface of trabecular bone [130, 131]. The exact spatial relationship of 
HSPCs and stromal progenitor cells within the marrow is not well defined, but 
both cell populations coexist in close proximity within the marrow, suggesting that 
they play an interactive role in regulating their microenvironment and influencing 
the function of the other. HSPC development and localization is directly 
influenced by factors synthesized during the osteogenic program of MSCs. The 
differentiation of bone marrow stromal cells toward the osteogenic lineage results 
in a cascade of events, from the early expression of osteopontin to the 
development of a mineralized extracellular matrix. For example, osteopontin 
which is a potent regulator of mineralization and one of the most abundant non-
collagenous proteins in bone [132], has been shown as a negative regulator of 
HSPC proliferation [133, 134], presumably facilitating the maintenance of a pool 
of hematopoietic progenitor cells within the marrow. Also, the mineral phase of 
bone is integral to the localization and adhesion of HSPCs within the endosteal 
niche, as HSPCs lacking the calcium-sensing receptor to detect the ionic content 
of the mineral phase do not function normally upon transplantation [135]. These 
examples support the concept that MSCs and osteoblastic cells actively regulate 
the function of HSPCs. The question remains whether HSPCs participate in 
completing this reciprocal relationship and how they influence the development 
and maintenance of the bone marrow niche. 
Recent reports suggest that HSPCs regulate bone formation through the 
production of BMP-2 and BMP-6 [136, 137). However, these studies emphasize 
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the effect of soluble signaling as the cell populations were physically separated in 
culture. Here we investigate the role of HSPCs in regulating the osteogenic 
differentiation of MSCs in vitro by examining the progression of osteogenesis 
through incorporating direct cell-cell interactions. Specifically, we evaluated the 
osteogenic differentiation of MSCs induced by dexamethasone treatment, and 
hypothesized that both cell-cell interactions and paracrine signaling provided by 
HSPCs would augment the osteogenic response of MSCs. To investigate our 
hypothesis, MSCs were co-cultured in direct contact with HSPCs in medium with 
or without the addition of dexamethasone, in order to explore the progression of 
osteogenesis and examine how HSPCs participate in the physical development 
of a mineralized niche environment in vitro. 
Materials and Methods 
MSC Isolation and Expansion 
MSCs were isolated from bone marrow collected and pooled from the 
femurs and tibias of twenty 8-10 week old C57BU6 mice (Jackson Laboratory, 
Bar Harbor, ME) according to previously established methods [138] and 
approved by the Institutional Animal Care and Use Committee of Baylor College 
of Medicine. Mice were anesthetized with isoflurane, euthanized via cervical 
dislocation, and then immersed in 70% ethanol. Femurs and tibias were excised 
and cleared of soft tissue. Bones were crushed using a mortar and pestle with 
Hank's balanced salt solution (HBSS) (Invitrogen, Carlsbad, CA), supplemented 
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with 2% fetal bovine serum (FBS) (Gemini Bio-Products, West Sacramento, CA), 
also with the addition of 1% antibiotics containing 10,000 U/mL penicillin and 
10,000 IJg/mL streptomycin (Invitrogen, Carlsbad, CA). The bone marrow 
suspension was filtered through a 100 IJm cell strainer to remove bone debris, 
followed by a 40 IJm cell strainer to obtain a single-cell suspension. Whole bone 
marrow was plated in tissue culture flasks with general expansion medium 
consisting of a-MEM, supplemented with 10% FBS, also with the addition of 1 % 
antibiotics containing penicillin and streptomycin. Adherent cells were cultured for 
7 days in general expansion medium with medium changes every 3 days. 
Following the primary culture period, MSCs were lifted with 0.25% trypsin and 
plated at low density for subculture expansion [139]. When confluent, MSCs were 
lifted and frozen in aliquots of medium containing 20% FBS and 10% dimethyl 
sulfoxide (DMSO). The adherent cells isolated from whole bone marrow and 
expanded through subculture will be referred to as the MSC population in 
subsequent co-cultures. 
HSPC Flow Cytometry Purification 
Following the same procedure described above to collect bone marrow 
from C57BU6 mice, the marrow was alternatively suspended in phosphate 
buffered saline (PBS), supplemented with 2% FBS, 2 mM EDT A, and 10 mM 
HEPES, also with the addition of 1 % antibiotics containing penicillin and 
streptomycin, then filtered through a 40 IJm cell strainer to obtain a single-cell 
suspension. Whole bone marrow was enriched immunomagnetically for Sca-1+ 
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cells using the EasySep Mouse SCA 1 Positive Selection Kit (Stem cell 
Technologies, Vancouver, BC, Canada) according to the manufacturer's 
instructions. In addition to labeling cells with phycoerythrin (PE) conjugated Sca-
1 as part of the EasySep Kit, cells were incubated on ice for 20 min with the 
following antibodies all at 1: 1 00 dilution; fluorescein isothiocyanate (FITC) 
conjugated c-Kit (BD Pharmingen, Franklin Lakes, NJ), PE-Cy5 conjugated Mac-
1, Gr-1, CD4, COB, B220, and Ter-119 (eBioscience, San Diego, CA, USA) as 
previously described [140). Cells were sorted for the cell surface phenotype c-Kit+ 
Sca-1+ Lineage- (KSL), comprised of hematopoietic stem and progenitor cells, 
using a Cytomation MoFlo cell sorter (Dako, Carpinteria, CA). The hematopoietic 
stem and progenitor cells isolated and purified from whole bone marrow will be 
referred to as the HSPC population in subsequent co-cultures. 
MSC-HSPC Direct Contact Co-culture 
Cryopreserved MSCs were thawed at 37°C and plated in tissue culture 
flasks with general medium for 24 h, then changed to complete osteogenic 
medium for an additional 6 days with medium changes every 2 days for 
osteogenic pre-culture [141, 142). Complete osteogenic medium for osteogenic 
pre-culture consisted of a-MEM, supplemented with 10% FBS, 10-8 M 
dexamethasone, 10 mM ~-glycerophosphate, and 50 mg/L ascorbic acid, also 
with the addition of 1 % antibiotics containing penicillin and streptomycin. In 
preparation for cell seeding, individual wells of 12-well plates were filled with 1 
mL of complete osteogenic medium either with or without the addition of 10-8 M 
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dexamethasone. Following the osteogenic pre-culture period, MSCs were lifted 
with 0.25% trypsin and seeded into 12-well plates at a density of 4 x 104 
cells/well. After allowing 24 h for MSCs to attach and form a monolayer, HSPCs 
were isolated as described above and seeded into wells designated for direct 
contact co-culture at either 400 cells/well or 1000 cells/well. The first medium 
change was performed after 4 days with subsequent medium changes every 2 
days thereafter. Sixteen wells were cultured for each culture group (MSC, 
CC400, CC1000) and dexamethasone treatment (-DEX and +DEX) for each 
culture time (8, 16, 24 days), at the end of which wells were rinsed with PBS in 
preparation for analysis. Two wells were fixed for scanning electron microscopy, 
two wells were stained to visualize alkaline phosphatase activity, and two wells 
were stained to visualize calcium deposition. Four wells were prepared to 
quantitatively assess cellularity and alkaline phosphatase activity, four wells to 
assess calcium content, and two wells to assess colony-forming capacity in 
methylcellulose medium. 
Scanning Electron Microscopy 
Culture wells for scanning electron microscopy were fixed with 10% 
neutral-buffered formalin (Fisher Scientific, Pittsburgh, PA) then rinsed with 
ddH20 and air-dried. Wells were cut out from the culture plates using an X-660 
laser Platform laser cutter (Universal laser Systems, Morningside, QlD, 
Australia) and mounted on aluminum stubs with conductive copper tape. 
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Samples were sputter coated with gold for 1 min prior to imaging using a Quanta 
400 SEM (FEI, Hillsboro, OR). 
Staining and Light Microscopy 
Alkaline phosphatase activity was visualized by staining culture wells 
using a Blue Alkaline Phosphatase Substrate Kit (Vector Laboratories, 
Burlingame, CA) according to the manufacturer's instructions. Reagents provided 
with the kit were mixed in recommended proportions into 100 mM Tris-HCI buffer 
with pH adjusted to 8.2. Cells were incubated with 500 IJL of the substrate 
solution and developed in the dark for 30 min at 37 cC. Following the staining 
procedure where cells expressing alkaline phosphatase were stained blue, wells 
were fixed with 10% neutral-buffered formalin then rinsed with ddH20. Plates 
were placed at an angle to air-dry then stored at 4 cC. Cells were imaged using 
an Imager.Z2 light microscope with an AxioCam MRc 5 video camera attachment 
(Zeiss, Thornwood, New York). 
Calcium deposition was visualized by staining culture wells with 40 mM 
Alizarin Red S (Sigma-Aldrich, St. Louis, MO) with pH adjusted to 4.1 using 
ammonium hydroxide [143]. Cells were fixed with 10% neutral-buffered formalin 
then rinsed with ddH20. Wells were incubated with 500 IJL of the Alizarin Red S 
solution for 30 min at room temperature. Wells were washed four times with 2 mL 
of ddH20 to remove any unincorporated dye. Calcium deposits indicative of 
matrix mineralization on differentiating cells were stained red. Plates were placed 
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at an angle to air-dry then stored at 4°C. Cells were imaged using an Imager.z2 
light microscope with an AxioCam MRc 5 video camera attachment. 
Osteogenic Differentiation Assays 
Cells from individual culture wells were lifted with 0.25% trypsin and 
placed in separate microcentrifuge tubes. Cell pellets were washed with PBS 
then 500 I-IL of ddH20 was added. Cells were lysed via three repetitions of a 
freeze and thaw cycle, where samples were frozen in liquid nitrogen for 10 min, 
thawed in a 37°C water bath for 10 min, and sonicated for 10 min. 
As a measure of cellularity, double-stranded DNA was quantified using the 
fluorometric PicoGreen assay (Invitrogen, Carlsbad, CA) with DNA standards 
[144]. Fluorescence was measured on an FL x800 plate reader (BioTek, 
Winooski, VT). DNA content is reported as I-Ig of DNA per well to assess 
cellularity. Alkaline phosphatase activity was determined by quantifying the 
enzyme-mediated dephosphorylation of the substrate p-nitrophenol phosphate to 
p-nitrophenol in a colorimetric assay (Sigma-Aldrich, St. Louis, MO) with p-
nitrophenol standards [145]. Absorbance was measured on a PowerWave x340 
plate reader (BioTek, Winooski, VT), with concentrated samples diluted as 
necessary to ensure absorbance readings within the linear range of the assay. 
Total alkaline phosphatase activity (ALP) per well is reported as pmol per hand 
normalized alkaline phosphatase activity (ALP/DNA) was calculated by dividing 
alkaline phosphatase activity over DNA content for each sample and is reported 
as pmol per h per I-Ig DNA as an early marker for osteogenic differentiation. 
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Calcium content was determined by quantifying free calcium ions in a 
colorimetric assay by first adding 500 JJL of 1 N acetic acid directly into each 
culture well. After allowing calcium deposits to dissolve, samples were collected 
and wells were rinsed with an additional 200 JJL of 1 N acetic acid. Calcium was 
quantified using the calcium assay (Genzyme, Cambridge, MA) with calcium 
chloride standards [146]. Absorbance was measured on a PowerWave x340 
plate reader, with concentrated samples diluted as necessary to ensure 
absorbance readings within the linear range of the assay. Total calcium content 
is reported as JJg of calcium per well and fold change in calcium content at each 
time point was calculated by normalizing calcium content to that of MSCs alone 
within each respective dexamethasone treatment to assess matrix mineralization 
as a late marker for osteogenic differentiation. 
Colony-forming Assay 
Cells from individual culture wells were lifted with 0.25% trypsin and 
placed in separate microcentrifuge tubes. The colony-forming capacity of HSPCs 
after each co-culture period was assessed by plating cells in Methocult GF 
M3434 methylcellulose-based medium (Stem cell Technologies, Vancouver, BC, 
Canada), then counting the number of colonies formed after 14 days [147]. 
Individual samples were first counted using a hemocytometer, aliquots of 104 
total cells were plated in 35 mm low attachment culture dishes (Stemcell 
Technologies, Vancouver, BC, Canada) with 1.1 mL of Methocult GF M3434, and 
then incubated for 14 days. Following the incubation period, colonies were 
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counted using gridded scoring transparencies on a Stemi 2000 C 
stereomicroscope (Zeiss, Thornwood, New York). Colony-forming unit counts are 
reported as colonies per 104 total cells to assess the number of functional 
hematopoietic stem and progenitor cells remaining within the total cell population 
after co-culture. 
Statistical Analysis 
Biochemical assay results to assess cellularity, alkaline phosphatase 
activity, and calcium content are reported as mean ± standard deviation for n = 4. 
A three-factor ANOVA was first performed to determine significant main effects 
or interactions between culture group (MSC, CC400, CC1000), dexamethasone 
treatment (-DEX and +DEX), and culture time (8, 16, 24 days). Multiple pairwise 
comparisons were then made using the Tukey procedure to determine significant 
differences. All statistical analyses were performed at a significance level of 5%. 
Colony-forming assay results are reported as mean ± standard deviation 
for n = 4. A two-factor ANOVA was first performed to determine significant main 
effects or interaction between dexamethasone treatment (-DEX and +DEX) and 
culture time (8, 16, 24 days). Multiple pairwise comparisons were then made 
using the Tukey procedure to determine significant differences. All statistical 
analyses were performed at a significance level of 5%. 
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Results 
Cellularity and Alkaline Phosphatase 
The influence of HSPCs on the osteogenic differentiation of MSCs in vitro 
was evaluated through direct contact co-culture with or without the addition of 
dexamethasone. Total DNA content per culture well was used to assess overall 
cellularity and proliferation throughout the culture period (Figure 111-1). Cellularity 
remained constant over time at approximately the initial seeding density for 
cultures of MSCs alone with dexamethasone (MSC+), whereas an increase in 
cellularity was observed from 8 to 16 days for cultures of MSCs alone without 
dexamethasone (MSC-). Unlike cultures of MSCs alone, cellularity increased 
over time for all co-cultures regardless of dexamethasone treatment, with 
significant differences compared to MSCs alone at 16 and 24 days within both 
dexamethasone treatments. Co-cultures with dexamethasone (CC400+ and 
CC1000+) resulted in lower cellularity at 16 and 24 days compared to those 
without dexamethasone (CC400- and CC1000-). 
Scanning electron micrographs were taken to visualize the surface 
morphology of culture wells with MSCs alone and MSCs and HSPCs in co-
culture, as well as changes in the overall topography over time (Figure 111-2). 
MSCs spread over the surface of culture wells forming a monolayer while HSPCs 
maintained a rounded phenotype. In short-term co-culture over 8 days, HSPCs 
appeared to grow on the surface of MSCs. In long-term co-culture over 24 days, 
HSPCs seemed to incorporate into the cell layer with MSCs. The cultures 
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acquired a rough texture after 24 days with the development of mineralized 
extracellular matrix containing mineral nodules. 
Total alkaline phosphatase activity (ALP) per culture well and alkaline 
phosphatase activity normalized to DNA content (ALP/DNA) were used to assess 
early osteogenic differentiation (Figure 111-3). Total ALP (Figure 111-3A) increased 
significantly in the first 8 days for all culture groups then remained constant over 
time for cultures of MSCs alone regardless of dexamethasone treatment. 
Although co-cultures with dexamethasone showed the same trend and ALP 
activity levels as MSCs alone, those without dexamethasone resulted in an 
increase in ALP over time, with significant differences compared to MSCs alone 
at 16 and 24 days. Co-cultures without dexamethasone resulted in higher ALP 
activity at 16 and 24 days compared to those with dexamethasone. ALP/DNA 
(Figure 111-38) remained constant over time at approximately the initial level at 
seeding for cultures of MSCs alone without dexamethasone, whereas ALP/DNA 
increased significantly in the first 8 days and peaked at 16 days for cultures of 
MSCs alone with dexamethasone. Although co-cultures without dexamethasone 
showed the same trend and ALP/DNA levels as MSCs alone, those with 
dexamethasone resulted in a peak in ALP/DNA at 8 days. Light micrographs 
were taken of culture wells stained blue to visualize the ALP expression of MSCs 
alone and MSCs and HSPCs in co-culture after 8 days (Figure 111-4). All cultures 
showed positive expression of ALP with fairly even distribution within the culture 
wells overall. Microscopy images revealed that most of the spread MSCs express 
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ALP with varying intensities of blue staining, while the rounded HSPCs did not 
appear to express ALP as evident in the lack of blue staining macroscopically. 
Calcium Deposition and Matrix Morphology 
Total calcium content per culture well and fold change in calcium content 
as compared to MSCs within each respective dexamethasone treatment were 
used to assess late osteogenic differentiation (Figure 111-5). Total calcium content 
(Figure 11I-5A) increased over time for cultures of MSCs alone regardless of 
dexamethasone treatment, with higher calcium deposition observed for cultures 
without dexamethasone at 16 and 24 days. Similar to cultures of MSCs alone, 
calcium content increased over time for all co-cultures regardless of 
dexamethasone treatment, also with higher calcium deposition observed for 
cultures without dexamethasone at 16 and 24 days. Fold change in calcium 
content for co-cultures was calculated by normalizing calcium content to that of 
MSCs alone within each respective dexamethasone treatment (Figure III-58). 
Only the low dose co-culture group with dexamethasone (CC400+) showed a 
significant difference in calcium content compared to MSCs alone with 
dexamethasone (MSC+). Fold change in calcium deposition for CC400+ was 5.8 
± 1.2 fold higher than MSC+ at 8 days and 5.5 ± 2.8 fold higher than MSC+ at 16 
days. Interestingly, there was no significant difference at 24 days. Light 
micrographs were taken of culture wells stained red to visualize the calcium 
deposition of MSCs alone and MSCs and HSPCs in co-culture after 24 days 
(Figure 111-6). Although all cultures showed calcium deposition with varying 
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intensities of red staining, the distribution of calcium deposits within the culture 
wells varied overall. Blank regions lacking calcium deposits were most apparent 
for co-cultures without dexamethasone, whereas calcium deposition appeared 
more evenly distributed for co-cultures with dexamethasone. Microscopy images 
revealed that the blank regions indeed had functional cells growing which did not 
stain red for calcium deposits. 
HSPC Colonies 
Colony-forming cell growth in methylcellulose medium was used to assess 
the colony-forming capacity of HSPCs after co-culture (Figure 111-7). Although the 
number of hematopoietic stem and progenitor cells significantly decreased in the 
first week of co-culture as compared to the initial HSPC population following 
FACS analysis prior to seeding (data not shown), more colonies remained with 
dexamethasone treatment in short-term co-culture. After 8 days of co-culture, 
colony-forming unit counts per 104 total cells for CC400+ was 35.3 ± 12.4 and for 
C400- was 3.3 ± 1.3. While dexamethasone treatment resulted in this significant 
difference in colony counts at 8 days, the number of colonies decreased over 
extended culture periods. 
Discussion 
The objective of this study was to investigate the influence of HSPCs on 
the osteogenic differentiation of MSCs through direct contact co-culture, to better 
understand the interactions of cellular components comprising the stem cell 
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niche under in vitro culture conditions. This study was designed to evaluate the 
osteogenic differentiation of MSCs in vitro induced by dexamethasone treatment, 
and to examine how the inclusion of HSPCs in co-culture would augment this 
differentiation response by providing a niche microenvironment consisting of both 
direct cell-cell interactions and paracrine signaling. 
Recent studies have reported that HSPCs actively participate in bone 
formation by producing BMP-2 and BMP-6 [136], especially when activated by 
elevated erythropoietin levels induced by acute bleeding [137]. Frequently in 
studies investigating the crosstalk between HSPCs and MSCs, the effect of 
soluble signaling is emphasized as HSPCs are cultured separately from MSCs in 
the top chambers of Transwell plates then assessed for osteoblastic colony 
formation at the end of culture [136, 148]. Here we investigated the progression 
of osteogenesis from induction to mineralized matrix production by incorporating 
direct cell-cell interactions in addition to paracrine signaling, which allowed us to 
examine how HSPCs participate in the physical development of a mineralized 
niche environment in vitro. 
Our results showed that HSPCs influenced the osteogenic differentiation 
of MSCs under in vitro culture conditions with dexamethasone. We observed that 
low doses of HSPCs co-cultured in direct contact with MSCs and exposed to 
dexamethasone treatment, reduced overall cellular proliferation, stimulated early 
alkaline phosphatase activity, and enhanced calcium deposition, thus supporting 
the progression of osteogenic differentiation in vitro. Additionally, we were able to 
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observe the physical interactions between HSPCs and differentiating MSCs 
throughout the progression of osteogenesis in vitro. 
Cellularity and proliferation throughout the culture period was evaluated by 
quantifying total DNA content per culture well. Cultures of MSCs alone, 
particularly with dexamethasone treatment, maintained similar cellularity over 24 
days of culture. Since cells were induced toward osteogenic differentiation in vitro 
with dexamethasone, we expect to see minimal proliferative activity as cells 
transition to an osteoblastic phenotype [149]. Although in all co-culture groups, 
the overall cell population rapidly proliferated, dexamethasone treatment 
significantly reduced cellularity after 16 and 24 days of culture. Observations 
from light microscopy and scanning electron microscopy suggest that the HSPC 
population proliferated quickly in co-culture while the MSC population maintained 
a confluent cell layer to support the growth and retention of HSPCs in vitro. Over 
an extended culture period however, HSPCs incorporated into the cell layer with 
MSCs and could possibly outcompete MSCs for space and nutrients. While in 
this study, the contribution of each cell population to the overall change in 
cellularity over time was not specifically assessed, we consider that HSPCs 
proliferate much more rapidly than MSCs in co-culture, as MSCs and osteogenic 
cells are often used as feeder layers to expand hematopoietic cell numbers ex 
vivo due to their supportive role in the stem cell niche [123-126]. However in 
those applications, dexamethasone is not included as a culture supplement, and 
thus the effects of both co-culture and dexamethasone on HSPCs in vitro are not 
known. Studies investigating glucocorticoid treatment through intraperitoneal 
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injections have shown hematoprotective effects of dexamethasone, promoting 
the quiescence of stem cells as seen in the maintenance of high colony-forming 
cell numbers even after cytotoxic chemotherapy [150, 151]. In exploring how 
HSPCs affect the progression of MSCs initiated toward osteogenic differentiation 
via dexamethasone exposure, we observed that dexamethasone may playa role 
in maintaining hematopoietic stem and progenitor cells in vitro. This is evidenced 
in the higher number of functional hematopoietic stem and progenitor cells within 
the total cell population that remain following short-term co-culture with 
dexamethasone, albeit those colony-forming cells decrease significantly in 
number over extended culture periods. Although the expansion of HSPCs ex vivo 
was not the focus of this current study, we found that dexamethasone as a 
culture supplement may be worth exploring in order to optimize co-culture 
conditions to permit the sustained expansion of HSPCs ex vivo. 
Alkaline phosphatase activity was used as an early marker for osteogenic 
differentiation as enzyme levels peak during the onset of osteogenic 
differentiation then decrease as cells progress toward an osteoblastic phenotype 
[149]. Dexamethasone treatment induced a significant increase in ALP/DNA in 
the first 8 days for all culture groups. While MSCs alone showed a clear peak in 
ALP/DNA at 16 days, the data suggest that the peak in ALP/DNA for co-culture 
groups may have occurred sooner within the first 8 days of culture, since 
ALP/DNA levels were already declining after 8 days. Thus, these trends in 
ALP/DNA imply that dexamethasone indeed promotes osteogenic differentiation 
with a characteristic peak in the profile of alkaline phosphatase expression we 
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typically observe in our osteogenic cultures [152-154], and that co-culture with 
HSPCs accelerates the osteogenic differentiation of MSCs in their transition to an 
osteoblastic phenotype. 
Since cell populations were not separated following co-culture, total 
alkaline phosphatase activity of the entire cell population as whole is also 
reported. Through macroscopic inspection following the staining procedure to 
visualize ALP expression at 8 days, HSPCs did not appear to stain for ALP 
activity as most of the staining was much more apparent and intense for the 
MSCs. While we do not know how the HSPC population contributes to 
quantitative ALP measurements, ALP expression has been documented for rare 
hematopoietic cells, particularly plasma cells as terminally differentiated 8-cells 
[155]. This may account for the higher levels of total ALP detected for co-cultures 
without dexamethasone, as the colony-forming assay revealed that cells rapidly 
differentiated into mature hematopoietic lineages within the first week of culture 
without dexamethasone treatment, as evident in the lower numbers of functional 
hematopoietic stem and progenitor cells remaining within the total cell population 
after co-culture. 
Calcium deposition was used as a late marker for osteogenic 
differentiation as cells with an osteoblastic phenotype deposit increasing 
amounts of extracellular matrix which mineralizes over time [149]. Calcium 
deposition increased over time for all culture groups regardless of 
dexamethasone treatment. Since mouse MSCs were expanded through a brief 
osteogenic pre-culture period with dexamethasone in order to direct cells toward 
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the osteoblastic lineage prior to establishing experimental cultures as with our 
previous osteogenic studies using rat MSCs [141, 142], this transient exposure 
may have initiated osteogenic progression with sustained effects even after the 
removal of dexamethasone in subsequent experimental cultures, similar to what 
has been documented for human MSCs [156]. Thus, the sustained effects of 
dexamethasone in initiating a pre-osteoblastic phenotype, likely contributed to 
the calcium deposition observed in our experimental cultures without 
dexamethasone. Interestingly, there is a qualitative difference in the distribution 
of cell populations and calcium deposits within co-cultures not treated with 
dexamethasone. Mineralized extracellular matrix appears to be localized to the 
MSC population, with large regions of the cultures wells occupied by the HSPC 
population that did not stain for calcium, in contrast to the more even staining 
seen for co-cultures treated with dexamethasone. 
When the calcium data for co-culture groups are normalized to that of 
MSCs alone within each respective dexamethasone treatment and considered as 
fold change in calcium content, it is apparent that in combination with 
dexamethasone treatment, a low dose of HSPCs in fact enhance calcium 
deposition at early time points. Over an extended culture period the signaling 
effects of HSPCs, which seem to accelerate osteogenic progression, dissipate as 
MSCs in all culture groups treated with dexamethasone converge to an 
osteoblastic phenotype. From the colony-forming assay, we see that it is the 
primitive hematopoietic stem and progenitor cells remaining in the total cell 
population following co-culture that exert this stimulatory effect on the osteogenic 
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differentiation of MSCs. On the contrary, if HSPCs differentiate into mature 
hematopoietic lineages in co-culture, then those hematopoietic cells lose their 
ability to augment the osteogenic progression of MSCs. Our findings in this study 
support the concept that not only do osteoblastic cells play a supportive role in 
maintaining hematopoietic cells, but that there is a reciprocal relationship 
whereby hematopoietic cells regulate osteoblastic cell function as active 
participants in the maintenance and development of the stem cell niche [136, 
148]. Interestingly, there appears to be an optimal cell density to achieve 
enhanced mineralization under co-culture conditions, as may be the case in the 
physiological environment where the balance between cell populations affect 
overall cell function and tissue morphology. Furthermore, in modeling the 
osteogenic development of MSCs through dexamethasone exposure, we 
observe that not only does dexamethasone assist in directing cells towards 
recreating a mineralized microenvironment in vitro via brief exposure in pre-
culture, but dexamethasone may also promote the maintenance of functional 
hematopoietic stem and progenitor cells in short-term co-culture. Thus, our 
investigation into the reciprocal relationship between the two major cell 
populations comprising the bone marrow niche under in vitro culture conditions, 
would allow the development of tissue engineering strategies further optimizing 
co-culture parameters to achieve expansion of hematopoietic cells ex vivo. 
Understanding the development of the bone marrow microenvironment and 
recreating key components or interactions in vitro brings us a step closer towards 
the realization of medical therapies utilizing culture expanded stem cells. 
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Conclusion 
In this work, we demonstrated that primitive hematopoietic stem and 
progenitor cells enhance the osteogenic differentiation of mesenchymal stem 
cells through both cell-cell interactions and paracrine signaling as facilitated 
through dexamethasone treatment in vitro. We were able to examine how 
HSPCs participate in the physical development of a mineralized niche 
environment through direct contact co-culture with MSCs. This study further 
supports the concept that HSPCs actively regulate the development and 
maintenance of the stem cell niche environment in which they reside. 
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Figure 111-1: Total DNA content of wells cultured with MSCs alone (MSC) or 
MSCs and HSPCs in co-culture (CC) at specified seeding densities (400 or 1000 
HSPCs seeded onto 40,000 MSCs) either with (+) or without (-) the addition of 
dexamethasone. Data are presented as mean ± standard deviation for n = 4. 
Within a specific treatment group, significant difference (p < 0.05) compared to 
MSCs at seeding and between time points is noted with (#). Within each culture 
group at a specific time point, significant difference (p < 0.05) between 
dexamethasone treatment is noted with (t). Within each dexamethasone group 
at a specific time point, significant difference (p < 0.05) compared to MSCs alone 
is noted with (*), with significant difference (p < 0.05) compared to all other 
groups noted with (**). 
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Figure 111-2: Representative scanning electron micrographs of wells cultured with 
MSCs alone (MSC) or MSCs and HSPCs in co-culture (CC) either with (+) or 
without (-) the addition of dexamethasone after 8 days (A-D) and 24 days (E-H). 
Arrows indicate areas of mineralization showing mineral nodules. The scale bar 
represents 100 J..Jm for all images with insets showing a 3x magnified view of 
HSPCs in more detail. 
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Figure 111-3: Alkaline phosphatase activity of wells cultured with MSCs alone 
(MSC) or MSCs and HSPCs in co-culture (CC) at specified seeding densities 
(400 or 1000 HSPCs seeded onto 40,000 MSCs) either with (+) or without (-) the 
addition of dexamethasone. Plots show total alkaline phosphatase activity (A) 
and alkaline phosphatase activity normalized to DNA content (8). Data are 
presented as mean ± standard deviation for n = 4. Within a specific treatment 
group, significant difference (p < 0.05) compared to MSCs at seeding and 
between time points is noted with (#) . Within each culture group at a specific time 
point, sign ificant difference (p < 0.05) between dexamethasone treatment is 
noted with (t) . Within each dexamethasone group at a specific time point, 
significant difference (p < 0.05) compared to MSCs alone is noted with (*), with 
significant difference (p < 0.05) compared to all other groups noted with (**) . 
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Figure 111-4: Alkaline phosphatase staining of wells after 8 days of culture with 
MSCs alone (MSC) or MSCs and HSPCs in co-culture (CC) at specified seeding 
densities (400 or 1000 HSPCs seeded onto 40,000 MSCs) either with (+) (D-F) 
or without (-) (A-C) the addition of dexamethasone. The scale bar represents 
200 IJm for all microscopy images. Insets show the overall alkaline phosphatase 
staining of the wells. 
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Figure 111-5: Calcium content of wells cultured with MSCs alone (MSC) or MSCs 
and HSPCs in co-culture (CC) at specified seeding densities (400 or 1000 
HSPCs seeded onto 40,000 MSCs) either with (+) or without (-) the addition of 
dexamethasone. Plots show total calcium content (A) and fold change in calcium 
content as compared to cultures with MSCs for each dexamethasone treatment 
at each time point (8). Data are presented as mean ± standard deviation for n = 
4 . Within a specific treatment group, significant difference (p < 0.05) between 
time points is noted with (#). With in each culture group at a specific time point, 
significant difference (p < 0.05) between dexamethasone treatment is noted with 
(t). Within each dexamethasone group at a specific time point, significant 
difference (p < 0.05) compared to MSCs alone is noted with (*), with significant 
difference (p < 0.05) compared to all other groups noted with (**) . 
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Figure 111-6: Alizarin Red staining of wells after 24 days of culture with MSCs 
alone (MSC) or MSCs and HSPCs in co-culture (CC) at specified seeding 
densities (400 or 1000 HSPCs seeded onto 40,000 MSCs) either with (+) (D-F) 
or without (-) (A-C) the addition of dexamethasone. The scale bar represents 
200 jJm for all microscopy images. Insets show the overall Alizarin Red staining 
of the wells. 
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Figure 111-7: Colony-forming unit counts of colonies derived in methylcellulose 
medium from the total cell population after co-culture (CC) at the specified 
seeding density (400 HSPCs seeded onto 40 ,000 MSCs) either with (+) or 
without (-) the addition of dexamethasone. Data are presented as mean ± 
standard deviation for n = 4. Within a specific treatment group, significant 
difference (p < 0.05) between time points is noted with (#). Significant difference 
(p < 0.05) between dexamethasone treatment is noted with (t). 
CHAPTER IV 
MODULATION OF OSTEOGENIC PROPERTIES OF 
BIODEGRADABLE POL YMERlEXTRACELLULAR MATRIX 
COMPOSITE SCAFFOLDS GENERATED WITH A FLOW 
PERFUSION BIOREACTOR t 
Abstract 
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In this study, composite scaffolds consisting of both synthetic and natural 
components with controllable properties were generated by incorporating 
mineralized extracellular matrix (ECM) and electrospun POIY(E-caprolactone) 
(PCl) microfiber scaffolds. Mesenchymal stem cells (MSCs) were cultured on 
PCl scaffolds under flow perfusion conditions with culture medium supplemented 
with dexamethasone to investigate the effect of culture duration on mineralized 
extracellular matrix deposition. MSCs differentiated down the osteogenic lineage 
and produced extracellular matrix with different compositions of mineral, 
collagen, and glycosaminoglycan with distinct morphologies at various stages of 
osteogenesis. To determine whether the presence and maturity of mineralized 
extracellular matrix influences osteogenic differentiation in vitro, PCLlECM 
constructs were decellularized to yield PCLlECM composite scaffolds that were 
t This chapter was published as follows: Liao J, Guo X, Nelson D, Kasper FK, Mikos AG. 
Modulation of osteogenic properties of biodegradable polymer/extracellular matrix scaffolds 
generated with a flow perfusion bioreactor. Acta Biomater 2010; 6(7): 2386-2393. 
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subsequently seeded with MSCs and cultured in the absence of dexamethasone. 
The presence of mineralized matrix reduced cellular proliferation while 
stimulating alkaline phosphatase activity with increasing amounts of calcium 
deposition over time. PCLlECM composite scaffolds containing the most mature 
mineralized matrix resulted in the most rapid increase and highest levels of 
alkaline phosphatase activity and calcium deposition compared to all other 
scaffold groups. Therefore, we demonstrate that mineralized extracellular matrix 
generated under controlled flow perfusion conditions can impart osteogenic 
properties to an osteoconductive polymer scaffold, and that the maturity of this 
matrix influences osteogenic differentiation in vitro, even in the absence of 
dexamethasone. 
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Introduction 
Bone has an innate ability to heal due to its vasculature and access to 
stem and progenitor cell populations. Although this innate healing response may 
repair bone fractures, large defects often require the aid of some scaffolding 
material to bridge the void space and facilitate bone regeneration. Currently, the 
most successful treatment for bone defects is autologous bone graft, which 
integrates well with the surrounding bone tissue and can be remodeled to restore 
structure and function. The success of autologous bone graft as a scaffold for 
bone regeneration is due to its osteoconductivity and osteoinductivity, as it not 
only supports stem and progenitor cell attachment, but also stimulates their 
osteogenic differentiation and bone formation. However, since autologous bone 
graft is harvested from healthy donor sites, drawbacks associated with its use 
include donor site morbidity and limited tissue availability [157]. Therefore, the 
need for alternative scaffolding materials with both osteoconductive and 
osteoinductive properties has launched the development of diverse biomaterials 
for bone regeneration applications. 
An ideal scaffold to facilitate bone regeneration should be biocompatible, 
provide structural support to the repair region, allow cell attachment and 
infiltration, induce osteogenic differentiation of stem and progenitor cells, 
stimulate bone formation, and be degradable over time, ultimately leaving bone 
tissue with native structure and function. The three main classes of scaffolding 
materials that have been investigated for bone regeneration include metals, 
ceramics, and polymers [158]. Of these materials, metals do not degrade (with 
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very few exceptions) and most ceramics are quite brittle. Polymer scaffolds on 
the other hand, can be synthesized with a wide variety of chemical and physical 
properties through tailored processing conditions. In particular, electrospun 
polymer scaffolds with a nonwoven fiber mesh structure are promising 
candidates for bone regeneration applications due to their large surface-to-
volume ratio for cell attachment and high interconnected porosity for cell and 
tissue infiltration. Here, we explore the application of electrospun poIY(E-
caprolactone) (PCl) microfiber scaffolds for bone regeneration, since PCl is a 
clinically applicable material regulated by the Food and Drug Administration that 
is both biocompatible and biodegradable. Electrospun PCl nanofiber scaffolds 
have been shown to support osteogenesis when seeded with mesenchymal stem 
cells (MSCs) and cultured in osteogenic cell culture medium containing 
dexamethasone [92]. As with many other porous scaffolds, electrospun PCl 
scaffolds are only osteoconductive, as they lack osteoinductive properties to 
stimulate osteogenesis on their own, and thus require the presence of 
exogenous induction agents such as dexamethasone or growth factors. 
Drawing from the success of bone matrix, whose osteoinductivity is 
attributed to the presence and association of native organic and inorganic 
components, we seek to impart osteogenic properties to electrospun PCl 
microfiber scaffolds by incorporating mineralized extracellular matrix generated 
by differentiating bone marrow derived MSCs under engineered conditions in 
vitro. Previously, we have successfully differentiated MSCs down the osteogenic 
lineage and demonstrated the deposition of bone-like extracellular matrix (ECM) 
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on titanium (Ti) fiber mesh scaffolds in a flow perfusion bioreactor system [153, 
159]. After decellularization, Ti/ECM composite scaffolds were shown to support 
osteogenic differentiation with enhanced calcium deposition [119, 152]. Although 
these studies with titanium scaffolds demonstrate osteogenic differentiation in 
vitro with either the application of fluid shear stresses or the delivery of 
dexamethasone, and have also shown promising results in vivo when implanted 
with cells, titanium is not degradable and will remain in the defect even after bone 
has regenerated [160, 161]. 
Ultimately, we envision creating a biodegradable osteoinductive scaffold 
that, when implanted, would recruit infiltrating host cells and induce their 
osteogenic differentiation and bone formation, either as a stand alone bone 
scaffold or as a vehicle for cell transplantation. Since MSCs are self-renewing 
multipotent stem cells that can be easily isolated from bone marrow, we stimulate 
their differentiation down the osteogenic lineage under flow perfusion culture 
conditions to where they deposit increasing amounts of mineralized extracellular 
matrix on electrospun PCl microfiber scaffolds. In this study, we capture the 
state of mineralized matrix at various stages of osteogenesis in generating 
PCLlECM (PE) composite scaffolds of various maturities, in order to evaluate 
how the presence and maturity of mineralized matrix influences the osteogenic 
differentiation of MSCs in vitro without the osteogenic cell culture supplement 
dexamethasone. For the fabrication of PCLlECM composite scaffolds, we 
hypothesized that exposing MSCs to dexamethasone and fluid shear stresses for 
various culture durations would stimulate the deposition of ECM containing 
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various quantities of minerals and signaling molecules. To evaluate the 
osteogenic properties of PCLlECM composite scaffolds, we hypothesized that 
the presence of mineralized matrix would induce MSC differentiation down the 
osteogenic lineage even without the addition of dexamethasone, by providing 
cells with a more biological microenvironment compared to plain PCl scaffolds. 
Furthermore, we hypothesized that the maturity of this mineralized matrix would 
modulate osteogenic differentiation through physical interaction with various 
compositions of matrix signals. To investigate our hypotheses, rat MSCs were 
seeded on electrospun PCl microfiber scaffolds and cultured in medium 
containing dexamethasone in the flow perfusion bioreactor to characterize the 
effect of culture duration on mineralized matrix composition and morphology. 
Resulting PCLlECM constructs were decellularized to yield PCLlECM composite 
scaffolds, which along with plain PCl scaffolds, were seeded with rat MSCs and 
cultured in medium without dexamethasone to determine how mineralized matrix 
maturity influences osteogenic differentiation in vitro as assessed through cellular 
proliferation, alkaline phosphatase activity, and calcium deposition. 
Materials and Methods 
Electrospinning 
Nonwoven PCl microfiber mats were fabricated using a horizontal 
electrospinning setup previously described, consisting of a 10 ml syringe fitted 
with a blunt tip needle and set on a syringe pump, an 18 gauge copper ring 19 
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cm in diameter placed 6 cm in front of the needle tip, a power supply with the 
positive lead split and connected to both the needle and copper ring, and a 0.3 
cm thick grounded copper plate covered with a glass collector plate [162]. Mats 
were electrospun to a targeted fiber diameter of 10 IJm using PCl (Sigma-
Aldrich, St. louis, MO) with Mn = 73,000 ± 9,000 and Mw = 154,000 ± 26,000 
from three samples relative to polystyrene as determined by gel permeation 
chromatography (Waters, Milford, MA) using a Phenogel 50 mm column 
(Phenomenex, Torrance, CA). Polymer was dissolved at 14 wt % in a solution 
with 5: 1 volume ratio of chloroform to methanol. The polymer solution was 
pumped through a 16 gauge blunt tip needle at a flow rate of 18 mLlh while 
charged with an applied voltage of 25.5 kV. The copper ring served to stabilize 
the electric field as the charged polymer jet whipped through the air toward the 
grounded copper plate positioned 33 cm away from the needle tip. The resulting 
PCl mat was then removed from the glass collector plate and dried in a 
desiccator. Prior to use, mats were inspected through scanning electron 
microscopy to visualize microfiber morphology and to confirm the average fiber 
diameter. 
Scaffold Preparation 
PCl scaffolds were die-punched from electrospun mats into 8 mm 
diameter disks with thicknesses between 0.95 and 1.05 mm. As previously 
characterized through mercury porosimetry, these scaffolds have a porosity of 
87% with an average pore size of 45 IJm [162]. PCl scaffolds were prepared for 
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cell culture by first sterilizing with ethylene oxide gas for 14 h, then aerating 
overnight to remove residual fumes. Scaffolds were then pre-wetted through a 
gradient series of ethanol from 100% to 70%, followed by three rinses in 
phosphate buffered saline (PBS), and incubated in cell culture medium overnight. 
To ensure complete wetting in each solution, scaffolds were centrifuged at each 
step of the pre-wetting process. Finally, PCl scaffolds were press-fitted into 
cassettes designed to confine the cell suspension during seeding and to be used 
in the flow perfusion bioreactor to generate PCLlECM composite scaffolds [121]. 
Cassettes holding the press-fitted scaffolds were placed in 6-well plates in 
preparation for seeding. 
PCUECM Mineralized Composite Scaffold Generation 
MSCs were harvested and pooled from the tibiae and femora of male 
Fischer 344 rats (Charles River, Wilmington, MA) weighing 150-175 g according 
to previously established methods [153, 163]. Rats were anesthetized with 4% 
isoflurane in oxygen then euthanized by carbon dioxide asphyxiation. The tibiae 
and femora were excised, cleared of soft tissue, then cut and flushed using an 18 
gauge needle with 5 ml of complete osteogenic medium consisting of a-MEM, 
supplemented with 10% fetal bovine serum (Cambrex, Walkersville, MO), 10-8 M 
dexamethasone, 10 mM l3-glycerophosphate, and 50 mg/l ascorbic acid, also 
with the addition of 1.25 mg/l amphotericin-B, 50 mg/l gentamicin, and 100 
mg/l ampicillin. Marrow pellets were triturated and plated in tissue culture flasks. 
Non-adherent cells were washed away after 24 h, and adherent cells were 
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cultured for 7 days in complete osteogenic medium with medium changes every 
2 days. After this primary culture period, MSCs were lifted with 2 ml of a 0.25% 
trypsin solution and suspended in culture medium for seeding onto press-fitted 
scaffolds at a seeding density of 250,000 cells in 200 IJl of medium within each 
cassette. Scaffolds were incubated with the seeding solution for 2 h, after which 
10 ml of medium was added to each well of the 6-well plates to fill the cassettes 
in which the scaffolds were held. 
PCUECM constructs containing mineralized extracellular matrix of various 
maturities were generated by culturing MSCs on electrospun PCl scaffolds for 4, 
8, 12, or 16 days under flow perfusion conditions with complete osteogenic 
medium containing dexamethasone. PCUECM constructs were decellularized to 
yield PCUECM composite scaffolds designated as PE4, PE8, PE12, and PE16 
experimental groups corresponding to their matrix maturities. To generate each 
batch of PCUECM constructs, MSCs were first harvested and pooled from five 
rats as described above and expanded through primary culture in complete 
osteogenic medium. Cells were then seeded onto PCl scaffolds and allowed to 
attach for 24 h, after which constructs were kept in their cassettes and 
transferred directly into the flow perfusion bioreactor, whose design and 
operation has been previously described in detail [121]. Medium was perfused 
through the press-fitted constructs at a flow rate of 0.7 mUmin with medium 
changes every 2 days. This flow rate was chosen to match the fluid shear stress 
applied in our previous study using titanium fiber mesh scaffolds [119]. At the end 
of each culture period, constructs were rinsed with PBS (without calcium and 
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magnesium) and stored in 1.5 ml ddH20 at -80°C. In addition to those 
PCUECM constructs generated to assess osteogenic differentiation, three 
constructs from each culture period were prepared for calcium, collagen, and 
glycosaminoglycan assays to characterize matrix composition and thus maturity, 
and two constructs from each culture period were prepared for x-ray imaging, 
histology, and scanning electron microscopy to visualize mineralized matrix 
morphology. 
PCUECM constructs were decellularized to yield PCUECM composite 
scaffolds via three consecutive cycles of a freeze and thaw process, in which 
constructs were frozen for 10 min in liquid nitrogen then thawed for 10 min in a 
37°C water bath [164]. This decellularization process has been shown to yield 
acellular constructs [152]. The resulting PCUECM composite scaffolds were then 
air-dried overnight, press-fitted into cassettes, sterilized with ethylene oxide gas 
for 14 h and aerated overnight in preparation for seeding. 
Mineralized Matrix Characterization 
After culturing MSCs on electrospun PCl microfiber scaffolds for 4, 8, 12, 
or 16 days under flow perfusion conditions, the resulting PCUECM constructs 
were characterized for their mineralized extracellular matrix composition and 
morphology. Calcium content was determined by extracting calcium in an acetic 
acid solution then measuring free calcium ions using the Calcium assay, further 
described in the following section. 
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Total collagen content was determined by measuring hydroxyproline in a 
colorimetric assay [165]. Samples taken from culture and rinsed with PBS were 
placed in 0.75 mL of a proteinase K solution and digested in a 56°C water bath 
for 16 h. The proteinase K solution consisted of 1 mg/mL proteinase K, 0.01 
mg/mL pepstatin A, and 0.185 mg/mL iodoacetamide, in a tris-EDTA buffer made 
by dissolving 6.055 mg/mL tris(hydroxymethyl aminomethane) and 0.372 mg/mL 
EDTA with pH adjusted to 7.6. Digested matrix components were extracted via 
three repetitions of a freeze, thaw, and sonication cycle, where samples were 
frozen for 30 min at -80°C, thawed at room temperature for 30 min, and 
sonicated for 30 min to allow matrix components into the solution. Hydroxyproline 
was quantified using a hydroxyproline assay as previously described [119]. After 
incubation for 30 min at 60°C, absorbance at 570 nm corresponding to 
hydroxyproline concentration was measured on a plate reader (BioTek 
PowerWave x340, Winooski, VT) and compared to a standard curve generated 
from known concentrations of hydroxyproline standards. Resulting 
hydroxyproline measurements in IJg were finally converted to collagen contents 
for each construct following a 1: 1 0 ratio of hydroxyproline to collagen [166]. 
Glycosaminoglycan content was determined by measuring 
glycosaminoglycan in a colorimetric assay [167]. Glycosaminoglycan was 
quantified in the supernatant previously obtained via proteinase K digestion using 
the dimethylmethylene blue assay (Sigma-Aldrich) as previously described [168]. 
After incubation for 10 min at room temperature, absorbance at 520 nm 
corresponding to glycosaminoglycan concentration, was measured on a plate 
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reader (BioTek PowerWave x340) and compared to a standard curve generated 
from known concentrations of chondroitin sulfate standards. Resulting 
glycosaminoglycan measurements in IJg were finally determined for each 
construct. 
Samples for x-ray imaging and histology were fixed in 10% neutral 
buffered formalin then cut in half and rinsed with 70% ethanol. Sample halves for 
x-ray imaging were air-dried overnight and imaged via x-ray (SkyScan 1172, 
Kontich, Belgium) according to the manufacturer's recommended voltage of 40 
kV with a current of 250 IJA as previously described [169]. Sample halves for 
histology were cryo-embedded in HistoPrep freezing medium (Fisher Scientific, 
Pittsburgh, PA) and stored at -80°C. Frozen sections 5 IJm thick were cut using a 
cryostat (Microm HM 500, Ramsey, MN), mounted onto Superfrost Excell glass 
slides, and placed on a 37°C slide warmer to facilitate adhesion. Sections were 
stained with hematoxylin and eosin to visualize the distribution of cells and 
extracellular matrix proteins. After mounting with Permount (Fisher Scientific), 
images were obtained using a light microscope (Nikon Eclipse E600, Melville, 
NY) with a video camera attachment (Sony DXC950P, New York, NY). Samples 
for scanning electron microscopy were fixed in glutaraldehyde and prepared for 
imaging as described in the scanning electron microscopy section. 
Osteogenic Differentiation without Dexamethasone 
To assess osteogenic differentiation on PCUECM composite scaffolds of 
various maturities, MSCs were first harvested and pooled from eight rats as 
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described above and expanded through primary culture in complete osteogenic 
medium. Cells were then seeded onto press-fitted experimental scaffolds PE4, 
PE8, PE12, and PE16, and also plain PCl control scaffolds at a seeding density 
of 250,000 cells in 200 IJl of medium without dexamethasone within each 
cassette. Scaffolds were incubated for 2 h with the seeding solution, after which 
10 ml of medium without dexamethasone was added to each well of the 6-well 
plates to fill the cassettes in which the scaffolds were held. After allowing 24 h for 
cell attachment, constructs were removed from their cassettes and transferred 
into 12-well plates with 3 ml of medium without dexamethasone and cultured 
static conditions for 4, 8, or 16 days with medium changes every 2 days. Five 
samples were cultured for each scaffold group (PCl, PE4, PE8, PE12, PE16) for 
each culture time (4, 8, 16 days), at the end of which, samples were rinsed with 
PBS (without calcium and magnesium) and stored for later analysis. Four 
samples were prepared for assessing construct cellularity, alkaline phosphatase 
activity, and calcium content, and one sample was prepared for scanning 
electron microscopy. 
Osteogenic Differentiation Assays 
Construct cellularity was determined by measuring double-stranded DNA 
in a fluorometric assay [144]. Samples taken from culture and rinsed with PBS 
were placed in 1 ml of ddH20, where DNA was extracted by lysing cells via 
three repetitions of a freeze and thaw cycle, in which samples were frozen for 10 
min in liquid nitrogen then thawed for 10 min in a 37°C water bath, and finally 
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sonicated for 10 min to allow DNA into the solution. DNA was quantified using 
the PicoGreen assay (Invitrogen, Carlsbad, CA) according to the manufacturer's 
instructions as previously described [152]. After incubation for 10 min room 
temperature, fluorescence at 520 nm corresponding to DNA concentration was 
measured on a plate reader (BioTek FL x800, Winooski, VT) and compared to a 
standard curve generated from known concentrations of DNA standards. 
Resulting DNA measurements in I-Ig were finally converted to cell numbers by 
correlating to DNA extracted from a known number of MSCs in order to assess 
cellular proliferation. 
Alkaline phosphatase activity was determined by measuring the enzyme-
mediated conversion of the substrate p-nitrophenyl phosphate to p-nitrophenol in 
a colorimetric assay [170]. ALP enzymatic activity was quantified in the 
supernatant previously obtained via freeze, thaw, and sonication, using the 
Alkaline Phosphatase assay (Sigma-Aldrich) as previously described [153]. After 
allowing the reaction to progress for 1 h at 37 °C, absorbance at 405 nm 
corresponding to p-nitrophenol concentration was measured on a plate reader 
(BioTek PowerWave x340) and compared to a standard curve generated from 
known concentrations of p-nitrophenol standards. Concentrated samples were 
diluted as needed to ensure readings within the linear range of the assay. 
Resulting ALP enzymatic activities as measured in pmol/hr corresponding to p-
nitrophenol production were finally normalized to cell numbers in order to assess 
ALP enzymatic activity per cell as an early stage marker for osteogenic 
differentiation. 
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Calcium content was determined by measuring free calcium ions in a 
colorimetric assay. After completing both DNA and ALP assays, samples were 
transferred into 1 mL of a 1 N acetic acid solution and placed on a shaker table at 
37°C overnight to dissolve calcium deposited in the constructs. Calcium was 
quantified in the acetic acid solution using the Calcium assay (Genzyme, 
Cambridge, MA) as previously described [153]. After incubation for 10 min at 
room temperature, absorbance at 650 nm corresponding to calcium 
concentration was measured on a plate reader (BioTek PowerWave x340) and 
compared to a standard curve generated from known concentrations of calcium 
chloride standards. Concentrated samples were diluted as needed to ensure 
readings within the linear range of the assay. Resulting calcium measurements in 
\-Ig were finally determined for each construct in order to assess calcium 
deposition as a late stage marker for osteogenic differentiation. 
Scanning Electron Microscopy 
Samples for scanning electron microscopy were fixed in 2.5% 
glutaraldehyde for 1 h, dehydrated through a gradient series of ethanol from 70% 
to 100%, air-dried overnight then cut and mounted on aluminum stubs to 
visualize the top surface of the constructs. Samples were sputter coated with 
gold for 1 min prior to imaging via SEM (FEI Quanta 400, Hillsboro, OR). 
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Statistical Analysis 
Characterization results for the composition of mineralized extracellular 
matrix contained within PCLlECM constructs following flow perfusion culture are 
reported as mean ± standard deviation for n = 3. A one-factor ANOVA was 
performed to determine whether culture duration (4, 8, 12, 16 days) had a 
significant effect. Comparisons were then made using the Tukey procedure to 
determine significant differences. 
Biochemical assay results to assess osteogenic differentiation following 
static culture without dexamethasone are reported as mean ± standard deviation 
for n = 4. A two-factor ANOVA was first performed to determine significant main 
effects or interaction between scaffold group (PCl, PE4, PE8, PE12, PE16) and 
culture time (4, 8, 16 days). Multiple pairwise comparisons were then made using 
the Tukey procedure to determine significant differences. All statistical analyses 
were performed at a significance level of 5%. 
Results 
PCUECM Mineralized Composite Characterization 
Mineralized extracellular matrix deposited on electrospun PCl microfiber 
scaffolds (fiber diameter 9.86 ± 0.56 !-1m) in generating PCLlECM (PE) constructs 
were characterized for their composition and morphology prior to 
decellularization. Calcium content, collagen content, and glycosaminoglycan 
content following flow perfusion culture for 4, 8, 12, and 16 days to generate 
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PE4, PES, PE12, and PE16 constructs, respectively (Figure IV-1). Calcium 
content significantly increased over time, with PE16 constructs containing the 
most calcium as compared to both PE4 and PES constructs. Although PE 12 
constructs contained more calcium than PE4 constructs, the calcium content of 
PE12 constructs was not statistically different from PES or PE16 constructs. In 
terms of extracellular matrix protein composition, the amount of collagen in PE16 
constructs was significantly higher than all other PCLlECM constructs, while 
glycosaminoglycan content was not significantly different among the PCLlECM 
constructs. Taking mineral content and glycosaminoglycan and collagen contents 
together, there was no significant difference between PE4 and PES constructs or 
between PES and PE12 constructs. However, there was a significant difference 
between PE12 and PE16 constructs in that PE16 constructs contained more 
collagen. 
Flow perfusion culture enhanced the distribution of cells and extracellular 
matrix proteins over time, as seen in the histological sections stained with 
hematoxylin and eosin (Figure IV-2A). Radiopaque regions of mineralized matrix 
increased over time, with PE16 constructs demonstrating the most minerals 
visible through x-ray imaging (Figure IV-2B). The surface morphology of 
PCLlECM constructs was visualized through scanning electron microscopy 
(Figure IV-2C). Extracellular matrix developed sparsely on PE4 constructs into a 
smooth surface seen on PES constructs. Mineral nodules on PE12 constructs 
eventually incorporated into a rough textured matrix on PE16 constructs. 
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Cellularity and Alkaline Phosphatase 
After PCLlECM constructs were decellularized, the resulting PCLlECM 
composite scaffolds along with plain PCl control scaffolds were seeded with 
MSCs to investigate how mineralized matrix maturity influences osteogenic 
differentiation in the absence of dexamethasone. Cellularity results showed that 
cell numbers remained constant over time at approximately the initial seeding 
density on all PCLlECM composite scaffolds, whereas an increase in cellularity 
was observed on PCl scaffolds from 4 to a days of culture (Figure IV-3). 
Although cellularity peaked at a days on PCl scaffolds (0.56x106 ± 0.14x106 
cells/construct) and was the highest compared to all PCUECM composite 
scaffolds, there was no statistical difference in cellularity among all scaffold 
groups after 16 days of culture. 
Alkaline phosphatase (ALP) activity per cell was used as an early stage 
marker for osteogenic differentiation (Figure IV-4). Cells cultured on PCl 
scaffolds did not show a statistically significant increase in ALP activity over time, 
whereas those cultured on all PCLlECM composite scaffolds demonstrated a 
significant increase in ALP activity from 4 to 16 days of culture with no 
observable peak. Furthermore, cells cultured on PE16 composite scaffolds also 
displayed a significant increase in ALP activity from 4 to a days of culture. 
Statistically significant differences in ALP levels compared to plain PCl controls 
were seen beginning at a days for PE16 and at 16 days for PE4, PEa, and PE12 
composite scaffolds. Cells cultured on PE16 composite scaffolds exhibited the 
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highest ALP activity compared to all other scaffold groups at a days (9.4 ± 1.0 
pmol/hr/cell) and 16 days (12.9 ± 5.0 pmol/hr/cell). 
Calcium Deposition and Matrix Morphology 
Calcium deposition per construct was used as a late stage marker for 
osteogenic differentiation (Figure IV-5). Cells cultured on PCl scaffolds and PE4 
composite scaffolds did not show a statistical increase in calcium deposition over 
time, whereas those cultured on PEa, PE12 and PE16 composite scaffolds 
demonstrated a significant increase in calcium deposition from 4 to 16 days of 
culture. Statistically significant differences in calcium content compared to plain 
PCl controls were seen beginning at 4 days for PE16 and at a days for PEa and 
PE12 composite scaffolds. PE16 composite scaffolds showed the highest 
calcium content compared to all other scaffold groups at 4 days (764 ± 150 I-Ig), a 
days (799 ± 136 I-Ig), and 16 days (1324 ± 253 I-Ig). 
Scanning electron micrographs were taken of the top surfaces of 
constructs to visualize the overall quality of the resulting extracellular matrix 
(Figure IV-6). Though PCUECM composite scaffolds started with an initial 
mineralized matrix while PCl scaffolds did not, the density and overall coverage 
of extracellular matrix on all scaffold groups increased over time, eventually to 
where scaffold fibers were no longer visible. The most striking differences in 
matrix quality were seen after 16 days of culture, where both PE12 and PE16 
composite scaffolds developed a distinguishingly rough texture, whereas all other 
scaffold groups retained a smooth appearance. PE16 composite scaffolds 
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seemed to take on this rough surface characteristic sooner than all other scaffold 
groups beginning after 8 days of culture. 
Discussion 
The objective of this study was to evaluate the osteogenic capacity of 
PCLlECM composite scaffolds in vitro. This study was designed to investigate 
the effects of mineralized extracellular matrix maturity on MSC differentiation 
down the osteogenic lineage in the absence of the osteogenic cell culture 
supplement dexamethasone. In order to determine whether exposing cells to a 
biomimetic microenvironment containing various compositions of matrix signals 
could influence their osteogenic differentiation response, PCLlECM composite 
scaffolds were generated by coating electrospun PCl microfiber scaffolds with 
natural mineralized extracellular matrix of various maturities, then seeded with 
MSCs and cultured in medium without the addition of dexamethasone. 
Exposing MSCs to both dexamethasone and fluid shear stresses in flow 
perfusion culture has been shown to synergistically enhance osteogenic 
differentiation and the distribution of mineralized extracellular matrix [153, 159]. 
Thus in this study, flow perfusion culture with dexamethasone was employed to 
generate PCLlECM constructs. In generating these PCLlECM constructs, we 
found that cells were able to penetrate throughout the interconnected porosity of 
electrospun PCl microfiber scaffolds and deposit increasing amounts of 
mineralized extracellular matrix with distinct compositions and morphologies over 
time. Since PCLlECM constructs were generated with MSCs induced down the 
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osteogenic pathway through exposure to osteogenic culture conditions, the 
resulting constructs at the end of each culture period contains extracellular matrix 
secreted by cells at various stages of osteogenesis after 4, 8, 12, and 16 days. 
As evident in our characterization of calcium, collagen, and glycosaminoglycan 
contents, we were able to generate PE4, PE8, PE12, and PE16 constructs 
containing various quantities of minerals and proteins by exposing MSCs to 
dexamethasone and fluid shear stresses for various culture durations. In addition 
to this quantitative difference in matrix composition, PCLlECM constructs also 
differed in appearance, as seen through x-ray images and scanning electron 
micrographs demonstrating mineralized matrix. Overall, the trends observed here 
using electrospun PCL microfiber scaffolds are consistent with previous studies 
in our group using titanium fiber mesh scaffolds, nonwoven poly(L-lactic acid) 
scaffolds, and fiber bonded starch-poIY(E-caprolactone) scaffolds [159, 171, 172). 
Although the flow rate in this study was chosen to match the fluid shear stress 
applied in our previous study using titanium fiber mesh scaffolds, electrospun 
PCL microfiber scaffolds have smaller pore sizes as compared to our previous 
scaffolding materials. Therefore, as extracellular matrix accumulates in the pore 
space over time, higher fluid shear forces are generated throughout the culture 
period. As a result, we were able to achieve much higher calcium deposition as 
compared to our previous scaffolding materials, since higher fluid shear stresses 
stimulate cells to deposit increasing amounts of matrix which mineralizes over 
time [153, 154). 
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PCLlECM constructs were decellularized to yield PCLlECM composite 
scaffolds containing mineralized matrix of various maturities. In order to evaluate 
osteogenic properties and the influence of mineralized matrix maturity on the 
osteogenic differentiation of MSCs in vitro, we seeded PCLlECM composite 
scaffolds along with plain PCl control scaffolds with MSCs and cultured them 
under static conditions without the addition of dexamethasone. Since 
dexamethasone is a potent synthetic glucocorticoid that is often necessary to 
drive osteogenic differentiation in vitro, we sought to isolate the effects of 
mineralized matrix on osteogenic differentiation by omitting this osteogenic 
supplement from the culture medium. 
Our results showed that the presence of mineralized matrix in PCLlECM 
composite scaffolds was able to induce the differentiation of MSCs down the 
osteogenic lineage as compared to plain PCl scaffolds. In general, we observed 
that mineralized matrix reduced cellular proliferation while stimulating alkaline 
phosphatase activity with increasing amounts of calcium deposition over time, 
thus indicating the progression of osteogenesis in vitro. Cells cultured on plain 
PCl scaffolds, on the other hand, exhibited minimal alkaline phosphatase activity 
and calcium deposition as expected, since they were not presented with any 
osteoinductive stimuli, specifically dexamethasone or extracellular matrix signals. 
Mineralized matrix maturity did not seem to differentially influence cellular 
proliferation since all PCLlECM composite scaffolds maintained similar cellularity 
over 16 days of culture. In fact, cells did not appear to proliferate on PCLlECM 
composite scaffolds as compared to the proliferation seen on plain PCl 
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scaffolds. This could be due to a difference in the physical morphology of the 
scaffolds, where PCUECM composite scaffolds are coated with mineralized 
matrix that may promote cell spreading to a confluent layer, while plain PCl 
scaffolds present a fiber morphology with a more open pore structure to support 
cellular proliferation. It is likely that cells seeded on the surface of PCUECM 
composite scaffolds grew to confluence since the layer of mineralized matrix may 
have been too dense for cells to remodel and penetrate under static culture 
conditions, as confirmed through histology (data not shown). Though in this 
study, in order to isolate the effects of mineralized matrix, it was necessary to 
evaluate osteogenic differentiation under static conditions and minimize 
confounding factors, namely fluid shear stresses introduced though flow 
perfusion culture, which would have facilitated cell penetration but also affected 
cellular response. 
Alkaline phosphatase is an enzyme responsible for the dephosphorylation 
of phosphates, and is used as an early stage marker for osteogenic 
differentiation. ALP levels peak as cells progress from a proliferative stage to 
depositing a mature extracellular matrix containing calcium phosphate [149]. 
Since PE16 composite scaffolds induced significantly higher levels of ALP 
activity as compared to all other scaffold groups after just 8 days, with the highest 
levels achieved among scaffold groups at 8 and 16 days of culture, it appears 
that a more mature mineralized matrix containing greater quantities of calcium 
and collagen induces a more rapid and robust osteogenic differentiation 
response. As compared to our previous studies on titanium fiber mesh scaffolds, 
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higher ALP levels were achieved in this study using extracellular matrix signals 
than with dexamethasone in static culture, while fluid shear stresses in flow 
perfusion culture without dexamethasone induced more ALP activity [119, 152, 
153]. 
Although our results did not show a peak in ALP activity for PCUECM 
composite scaffolds, enzyme levels did not significantly increase from 8 to 16 
days of culture, implying that cellular activity may just be starting to shift toward 
the synthesis of a more mature matrix. This shift in cellular activity is supported 
by the calcium deposition results, used here as a late stage marker of osteogenic 
differentiation. An increase in calcium content was only observed after 16 days of 
culture for PE8, PE12, and PE16 composite scaffolds. It is important to 
emphasize that PCUECM composite scaffold groups each began with different 
amounts of calcium deposited during the generation of mineralized matrix in flow 
perfusion culture. Although the initial quantity of minerals was characterized 
following each culture period, the actual mineral content of PCUECM composite 
scaffolds may be reduced following the freeze-thaw decellularization process. 
Nevertheless, even though minerals present in PCUECM composite scaffolds 
inherently contribute to the enhanced calcium contents seen for more mature 
scaffold groups, the increase in ALP activity is indicative of osteogenic 
differentiation, which is especially apparent in MSCs cultured for only 8 days on 
PE 16 composite scaffolds. Due to the initial variation in calcium content among 
PCUECM composite scaffolds, it is difficult to compare the resulting calcium 
content between scaffold groups, but rather more informative to note the change 
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in calcium content over time for each scaffold group. In doing so, we see that 
cells cultured on plain PCl scaffolds and PE4 composite scaffolds do not 
produce much matrix even after 16 days of culture. In contrast, cells cultured on 
PE8, PE12, and PE16 composite scaffolds require exposure to matrix signals for 
at least 16 days in order to differentiate and lay down a mineralized extracellular 
matrix of their own. The progression in matrix maturation is further observed 
through scanning electron micrographs showing the initial deposition of a smooth 
collagen matrix which eventually develops into a rough mineralized matrix over 
time. 
We presume that the osteoinductive effects of mineralized extracellular 
matrix observed in this study involve specific cell-matrix interactions, since 
foreseeable confounding effects due to dexamethasone supplementation and 
fluid shear stresses were excluded from this study. In addition to the 
characterized presence of calcium, collagen, and glycosaminoglycan, 
mineralized matrix generated in the same flow perfusion bioreactor system has 
been shown to contain active bone-related growth factors, particularly BMP-2, 
FGF-2, VEGF, and TGF-131, found to be localized and most prevalent at the 
surfaces of constructs as detected through immunohistochemical analysis [173]. 
Therefore, in generating PCUECM composite scaffolds of various maturities that 
contain increasing quantities of minerals and proteins with increasing culture 
duration, we expect the presence of these signaling molecules to increase as 
well. Cells seeded onto PCUECM composite scaffolds would directly interact 
with not only physical matrix components but also localized growth factors that 
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together, regulate osteogenic differentiation. In addition to cell-matrix interactions 
with native bone tissue components, surface roughness due to calcium 
phosphate incorporation into the mineralized matrix on PCLlECM composite 
scaffolds may have also influenced cellular response. The difference in surface 
morphology down to nanoscale features could affect cell attachment and 
migration, with possible effects on osteogenic differentiation [174-176]. 
Accordingly, we found that a more mature mineralized matrix containing more 
minerals, collagen, and glycosaminoglycan possesses greater osteogenic ability 
than less developed matrices, possibly due to the presence of more bone 
signaling molecules and increased surface roughness. 
Conclusion 
In this work, we demonstrate that the presence of mineralized extracellular 
matrix on electrospun PCl microfiber scaffolds imparts osteogenic properties to 
an otherwise inert biomaterial, as evident in its ability to stimulate osteogenic 
differentiation of MSCs in vitro in the absence of the osteogenic supplement 
dexamethasone. Furthermore, we show that the maturity of this mineralized 
matrix modulates osteogenic differentiation, providing insight towards the 
development of osteoinductive scaffolding materials with controllable 
characteristics for bone regeneration. 
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Figure IV-1: Matrix composition of PCL/ECM (PE) constructs generated in flow 
perfusion culture of increasing durations (4, 8, 12, and 16 days) for PE4, PE8, 
PE12, and PE16 constructs. Plots show (A) glycosaminoglycan and collagen 
contents and (8) calcium content as mean ± standard deviation for n = 3. 
Significant difference (p < 0.05) between time points is noted with (#). 
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Figure IV-2: Matrix morphology of PCL/ECM (PE) constructs generated in flow 
perfusion culture of increasing durations (4, 8, 12, and 16 days) for PE4, PE8, 
PE12, and PE16 constructs. Histological sections stained with hematoxylin and 
eosin to visualize the distribution of cells and extracellular matrix proteins are 
shown in (A) with the scale bar representing 100 J-Im. X-ray images depicting 
radiopaque regions of mineralized matrix are shown in (8) with the scale bar 
representing 1 mm. Scanning electron micrographs of the top surface illustrating 
surface characteristics are shown in (C) with arrows indicating mineral nodules 
and the scale bar representing 100 J-Im. 
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Figure IV-3: Cellularity of plain PCl scaffolds and PCl/ECM (PE) composite 
scaffolds seeded with MSCs and cultured in static conditions without 
dexamethasone for 16 days. PE4, PE8, PE12, and PE16 composite scaffolds 
contain mineralized matrix of various maturities generated in flow perfusion 
culture of increasing durations. Data are presented as mean ± standard deviation 
for n = 4. Within a specific scaffold group, significant difference (p < 0.05) 
between time points is noted with (#). At a specific time point, significant 
difference (p < 0.05) compared to all other scaffold groups is noted with (t). 
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Figure IV-4: Alkaline phosphatase activity of plain PCl scaffolds and PCl/ECM 
(PE) composite scaffolds seeded with MSCs and cultured in static conditions 
without dexamethasone for 16 days. PE4, PE8, PE12, and PE16 composite 
scaffolds contain mineralized matrix of various maturities generated in flow 
perfusion culture of increasing durations. Data are presented as mean ± standard 
deviation for n = 4. Within a specific scaffold group, significant difference (p < 
0.05) between time points is noted with (#) . At a specific time point, significant 
difference (p < 0.05) compared to plain PCl controls is noted with (*), with 
significant difference (p < 0.05) compared to all other scaffold groups noted with 
(t )· 
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Figure IV-5: Calcium content of plain PCl scaffolds and PCl/ECM (PE) 
composite scaffolds seeded with MSCs and cultured in static conditions without 
dexamethasone for 16 days. PE4, PE8, PE12, and PE16 composite scaffolds 
contain mineralized matrix of various maturities generated in flow perfusion 
culture of increasing durations. Data are presented as mean ± standard deviation 
for n = 4. Within a specific scaffold group, significant difference (p < 0.05) 
between time points is noted with (#). At a specific time point, significant 
difference (p < 0.05) compared to plain PCl controls is noted with (*) , with 
significant difference (p < 0.05) compared to all other scaffold groups noted with 
(t) . 
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Figure IV-6: Representative scanning electron micrographs of the top surfaces 
of plain PCl scaffolds and PCl/ECM (PE) composite scaffolds seeded with 
MSCs and cultured in static conditions without dexamethasone for 16 days. PE4, 
PE8, PE12, and PE16 composite scaffolds contain mineralized matrix of various 
maturities generated in flow perfusion culture of increasing durations. For each 
scaffold group, three rows of images are shown for constructs after (A) 4 days of 
culture, (8) 8 days of culture, and (C) 16 days of culture. The scale bar shown 
represents 1 00 ~m and applies to all images. 
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CHAPTER V 
BIOACTIVE POL YMERlEXTRACELLULAR MATRIX SCAFFOLDS 
FABRICATED WITH A FLOW PERFUSION BIOREACTOR FOR 
CARTILAGE TISSUE ENGINEERING t 
Abstract 
In this study, electrospun poIY(E-caprolactone) (PCl) microfiber scaffolds, 
coated with cartilaginous extracellular matrix (ECM), were fabricated by first 
culturing chondrocytes under dynamic conditions in a flow perfusion bioreactor 
and then decellularizing the cellular constructs. The decellularization procedure 
yielded acellular PCUECM composite scaffolds containing glycosaminoglycan 
and collagen. PCUECM composite scaffolds were evaluated for their ability to 
support the chondrogenic differentiation of mesenchymal stem cells (MSCs) in 
vitro using serum-free medium with or without the addition of transforming growth 
factor-f31 (TGF-f31). PCUECM composite scaffolds supported chondrogenic 
differentiation induced by TGF-f31 exposure, as evidenced in the up-regulation of 
aggrecan (11.6 ± 3.8 fold) and collagen type II (668.4 ± 317.7 fold) gene 
expression. The presence of cartilaginous matrix alone reduced collagen type I 
gene expression to levels observed with TGF-f31 treatment. Cartilaginous matrix 
t This chapter was published as follows: Liao J, Guo X, Grande-Allen KJ, Kasper FK, Mikos AG. 
Bioactive polymer/extracellular matrix scaffolds fabricated with a flow perfusion bioreactor for 
cartilage tissue engineering. Biomaterials 2010; 31 (34): 8911-8920. 
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further enhanced the effects of growth factor treatment on MSC chondrogenesis 
as evidenced in the higher glycosaminoglycan synthetic activity for cells cultured 
on PCUECM composite scaffolds. Therefore, flow perfusion culture of 
chondrocytes on electrospun microfiber scaffolds is a promising method to 
fabricate polymer/extracellular matrix composite scaffolds that incorporate both 
natural and synthetic components to provide biological signals for cartilage tissue 
engineering applications. 
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Introduction 
Articular cartilage serves a vital role in normal joint function, but has a 
limited capacity for regeneration once injured or damaged due to its avascular 
nature and sparse cell population. Clinical procedures that penetrate the 
subchondral bone to trigger an intrinsic wound healing response, such as 
abrasion or microfracture, typically result in fibrous tissue which lacks the 
structure and function of native cartilage [177]. Other clinical approaches 
involving the transplantation of osteochondral grafts or autologous chondrocytes 
require tissue biopsies that damage otherwise healthy cartilage [178, 179]. 
Therefore, tissue engineering strategies incorporating scaffolds, cells, and 
bioactive factors to regenerate functional cartilage tissue have emerged as a 
promising alternative. 
Mesenchymal stem cells (MSCs) and chondrocytes are often targeted for 
cartilage tissue engineering due to their vital role in native cartilage formation and 
function. Since their cellular processes are influenced by both physical and 
biological signals, effective biomaterial scaffolds for cartilage repair must not only 
act as temporary supports for tissue growth, but also as instructive 
microenvironments to guide cellular function. Thus extracellular matrix 
components, either as isolated proteins or with complex compositions, have been 
investigated as scaffolding materials for cartilage tissue engineering in an effort 
to stimulate chondrogenesis by culturing cells within a biological 
microenvironment [180]. 
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Recently, sponge-like scaffolds fabricated using collagen and 
glycosaminoglycan, or purely from native cartilage extracellular matrix 
components, have been shown to support MSC chondrogenic differentiation 
[181, 182]. Although MSCs were exposed to chondroinductive growth factors 
either during expansion or throughout the culture period, these studies 
demonstrate the application of natural matrices with promising results. 
Fabricating cartilaginous scaffolds typically entails reconstituting proteins and 
may even involve crosslinking to strengthen the matrix; processing conditions 
which can affect matrix biochemistry. Still these scaffolds, even after prolonged 
culture in vitro, lack sufficient mechanical properties to support joint function 
during tissue regeneration [182]. 
Synthetic polymers on the other hand, are more robust scaffolding 
materials whose physical properties can be easily controlled through tailored 
processing conditions. Electrospun polymer scaffolds, in particular, are promising 
candidates for tissue engineering applications due to their nonwoven fiber mesh 
structure, which imparts a large surface-to-volume ratio for cell attachment and 
offers a high interconnected porosity for cell and tissue infiltration. Electrospun 
poIY(E-caprolactone) (PCl) nanofiber scaffolds have been shown to support the 
attachment and proliferation of chondrocytes and also MSC differentiation along 
the chondrogenic lineage when cultured with transforming growth factor-j31 
(TGF-j31) [103, 183]. 
Previously, we have demonstrated that culturing MSCs in a flow perfusion 
bioreactor on fiber mesh scaffolds in the presence of osteogenic cell culture 
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supplements, promotes the deposition of an extracellular matrix (ECM) 
containing both structural matrix proteins and bioactive growth factors [173]. 
Upon decellularization, composite scaffolds containing mineralized matrix were 
capable of inducing MSC osteogenic differentiation even in the absence of 
dexamethasone, the cell culture supplement often required to stimulate 
osteogenic differentiation in vitro [119, 184]. Here, we seek to develop composite 
scaffolds for cartilage repair by incorporating cartilaginous matrix generated 
under fluid flow perfusion conditions on electrospun PCl microfiber scaffolds. By 
employing both natural and synthetic components in a tissue engineering 
scaffold, we aim to provide a more physiological microenvironment containing 
both structural and biological signals to guide MSC chondrogenic differentiation, 
while at the same time maintaining physical scaffolding properties in a 
controllable polymeric system. 
In this study, we fabricate PCUECM composite scaffolds consisting of 
electrospun microfibers coated with cartilaginous extracellular matrix, and 
evaluate their ability to support the chondrogenic differentiation of MSCs in vitro. 
For the fabrication of PCUECM composite scaffolds, we hypothesized that 
culturing chondrocytes on PCl scaffolds under dynamic conditions in a flow 
perfusion bioreactor would stimulate the deposition of cartilaginous ECM that 
remains even after decellularization. In an effort to evaluate the chondrogenic 
properties of PCUECM composite scaffolds, we hypothesized that PCUECM 
scaffolds would support MSC differentiation along the chondrogenic lineage 
induced by TGF-~1 exposure, and that the presence of cartilaginous matrix 
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would further enhance this differentiation response by providing cells with a more 
biological microenvironment compared to plain PCL scaffolds. To investigate our 
hypotheses, bovine chondrocytes were seeded on electrospun PCL microfiber 
scaffolds and cultured in a flow perfusion bioreactor. The resulting PCUECM 
constructs were decellularized to yield PCUECM composite scaffolds, which 
were characterized for their cartilaginous matrix morphology and composition in 
response to the decellularization procedure. PCUECM composite scaffolds as 
well as plain PCL scaffolds were seeded with rabbit MSCs and cultured in serum-
free medium either with our without the addition of TGF-~1. Constructs were 
evaluated for cellularity, glycosaminoglycan content (GAG) and synthetic activity 
(GAG/DNA), and gene expression through real-time reverse transcription 
polymerase chain reaction (RT-PCR), to determine how physical matrix 
interactions and biochemical signaling influence chondrogenic differentiation in 
vitro. 
Materials and Methods 
Electrospinning 
Nonwoven PCL microfiber mats were fabricated using a horizontal 
electrospinning setup with a copper ring to stabilize the electric field as previously 
described [162]. Mats were electrospun to a targeted fiber diameter of 10 !-1m 
using a solution of 14 wt % PCL (Sigma-Aldrich, st. Louis, MO) in a 5:1 volume 
ratio of chloroform to methanol. PCL with Mn = 73,000 ± 9,000 and Mw = 
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154,000 ± 26,000 was characterized by gel permeation chromatography (Waters, 
Milford, MA) from three samples relative to polystyrene. The polymer solution 
was pumped at a flow rate of 18 mLlh while charged with an applied voltage of 
25.5 kV to draw microfibers toward the collector plate [184]. The resulting PCl 
mat was aerated, inspected for consistent microfiber morphology, and stored in a 
desiccator. 
Scaffold Preparation 
PCl mats were die-punched into scaffolds 6 mm in diameter with 
thicknesses between 0.95 and 1.05 mm. As previously characterized through 
scanning electron microscopy and mercury porosimetry, these scaffolds had an 
average fiber diameter of 9.86 ± 0.56 IJm and a porosity of 87% with an average 
pore size of 45 IJm [162,184]. Prior to use, PCl scaffolds were sterilized with 
ethylene oxide gas for 14 h and aerated overnight to remove residual fumes. 
Scaffolds were pre-wetted by centrifuging through a graded series of ethanol 
from 100% to 70%, followed by three rinses in phosphate buffered saline (PBS), 
and incubated in cell culture medium overnight. In preparation for cell seeding, 
scaffolds were press-fitted into cassettes designed to confine the cell suspension 
and to be used in the flow perfusion bioreactor [121]. 
PCUECM Cartilaginous Composite Scaffold Generation 
Chondrocytes were harvested and pooled from cartilage collected from 
the femoral condyle area of four young calves through tissue obtained from 
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Research 87 (Research 87, Boylston, MA) according to previously established 
methods [185]. Cartilage was collected from the condyles, washed with PBS, and 
digested in culture medium containing 2 mg/mL collagenase (Worthington, 
Lakewood, NJ) while incubating at 37°C overnight. Chondrocytes were frozen in 
aliquots of medium containing 20% fetal bovine serum (FBS) and 10% dimethyl 
sulfoxide (DMSO). 
PCLlECM constructs containing cartilaginous extracellular matrix were 
generated by culturing chondrocytes on electrospun microfiber scaffolds under 
dynamic conditions in the flow perfusion bioreactor for 9 days, then decellularized 
through a freeze and thaw procedure to yield PCLlECM composite scaffolds 
(Figure V-1). Cryopreserved chondrocytes were first thawed at 37°C and plated 
in tissue culture flasks with chondrocyte culture medium consisting of DMEM, 
supplemented with 10% FBS (Gemini Bio-Products, West Sacramento, CA), 1 % 
non-essential amino acids, 0.4 mM proline, 10 mM HEPES buffer, and 50 mg/L 
ascorbic acid, also with the addition of penicillin, streptomycin, and fungizone 
(Invitrogen, Carlsbad, CA). Primary chondrocytes were cultured for 7 days in 
chondrocyte culture medium with medium changes every 3 days. Chondrocytes 
were lifted with 0.05% trypsin and suspended in culture medium for seeding onto 
press-fitted scaffolds at a seeding density of 150,000 cells in 200 IJL of medium 
within each cassette. Scaffolds were incubated with the seeding solution for 2 h 
then medium was added to fill each cassette. After allowing 24 h for cell 
attachment, constructs in their cassettes were transferred directly into the flow 
perfusion bioreactor and cultured for 9 days with medium changes every 3 days. 
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Medium was perfused through the press-fitted constructs at a flow rate of 0.3 
mUmin to provide cells with some mechanical stimulation and enhance 
metabolic transport [121]. 
At the end of culture, constructs were rinsed with PBS and stored in 1.5 
mL ddH20 at -80°C. PCUECM constructs were decellularized to yield PCUECM 
composite scaffolds via three consecutive cycles of a freeze and thaw procedure, 
in which constructs were frozen for 10 min in liquid nitrogen then thawed for 10 
min in a 37°C water bath [164]. Even though this decellularization procedure has 
been shown to yield acellular constructs [152], samples were prepared for 
scanning electron microscopy, histology, and glycosaminoglycan and collagen 
assays to assess matrix morphology and composition before and after 
decellularization. The resulting PCUECM composite scaffolds were air-dried 
overnight, press-fitted into cassettes, sterilized with ethylene oxide gas for 14 h 
and aerated overnight in preparation for seeding. 
Cartilaginous Matrix Characterization 
Samples for histology were fixed in 10% neutral buffered formalin (Fisher 
Scientific, Pittsburgh, PA) then immersed in 70% ethanol prior to embedding in 
HistoPrep freezing medium (Fisher Scientific, Pittsburgh, PA) and stored at -80 
°C. Frozen sections 5 IJm thick were cut using a cryostat (Leica Biosystems, 
Richmond, IL), mounted onto Superfrost Excell glass slides (Fisher Scientific, 
Pittsburgh, PA), and placed on a 37°C slide warmer to facilitate adhesion. 
Sections were stained with hematoxylin to visualize the distribution of cells, and 
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Safranin 0 to visualize the distribution of cartilaginous extracellular matrix. 
Images were obtained using a light microscope (Nikon Eclipse E600, Melville, 
NY) with a video camera attachment (Sony DXC950P, New York, NY). 
Samples for biochemical assays were digested in 500 IJL of a proteinase 
K solution while incubating in a 56°C water bath for 16 h. The proteinase K 
solution consisted of 1 mg/mL proteinase K, 0.01 mg/mL pepstatin A, and 0.185 
mg/mL iodoacetamide, in a tris-EDTA buffer made by dissolving 6.055 mg/mL 
tris(hydroxymethyl aminomethane) and 0.372 mg/mL EDTA with pH adjusted to 
7.6. Matrix components were extracted via three repetitions of a freeze, thaw, 
and sonication cycle, where samples were frozen for 30 min at -80°C, thawed for 
30 min at room temperature, and sonicated for 30 min in order to allow matrix 
components into the solution. 
Total collagen content was determined by quantifying hydroxyproline 
using the colorimetric hydroxyproline assay and hydroxyproline standards as 
previously described [184]. Absorbance was measured on a plate reader (BioTek 
PowerWave, Winooski, VT). Resulting hydroxyproline measurements in IJg were 
converted to collagen contents for each sample following a 1: 1 0 ratio of 
hydroxyproline to collagen [165]. 
Glycosaminoglycan content was determined by quantifying GAG using the 
colorimetric dimethylmethylene blue assay (Sigma-Aldrich, St. Louis, MO) and 
chondroitin sulfate standards as previously described [184]. Absorbance was 
measured on a plate reader (BioTek PowerWave, Winooski, VT). Resulting GAG 
measurements in IJg were determined for each sample. For glycosaminoglycan 
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synthetic activity, the resulting GAG amounts were normalized to the amount of 
DNA for each sample. 
Chondrogenic Differentiation with TGF-fJ1 
MSCs were harvested from bone marrow aspirates taken from the tibiae 
of six male New Zealand white rabbits (Charles River, Wilmington, MA) weighing 
2.8-3.0 kg according to previously established methods [186]. Bone marrow from 
each leg was aspirated into a 10 mL syringe containing 5,000 U/mL heparin to 
prevent coagulation. The experimental protocol for this study was reviewed and 
approved by the Institutional Animal Care and Use Committee of Rice University, 
and all procedures were conducted according to the Principles of Laboratory 
Animal Care (NIH Publication No. 85-23, Revised 1985). The bone marrow was 
plated in tissue culture flasks with general expansion medium consisting of 
DMEM, supplemented with 10% FBS (Gemini Bio-Products, West Sacramento, 
CA), also with the addition of penicillin, streptomycin, and fungizone (Invitrogen, 
Carlsbad, CA). Non-adherent cells were washed away after 72 h, and adherent 
cells were cultured for 14 days in general expansion medium with medium 
changes every 3 days. After this primary culture period, MSCs were lifted with 
0.05% trypsin and pooled from all six rabbits then frozen in aliquots of medium 
containing 20% FBS and 10% DMSO, in order to reduce variation between 
individual animals [187]. 
Cryopreserved MSCs were thawed at 37°C, plated in tissue culture 
flasks, and expanded to passage three with general expansion medium for the 
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differentiation study (Figure V-1). MSCs were then trypsinized and seeded onto 
press-fitted experimental PCLlECM composite scaffolds and also plain PCl 
control scaffolds at a density of 150,000 cells in 200 IJl of medium within each 
cassette. Scaffolds were incubated with the seeding solution for 2 h then serum-
free chondrogenic medium was added to fill each cassette consisting of DMEM, 
supplemented with 1 % ITS+ Premix (BD Biosciences, San Jose, CA), 10-7 M 
dexamethasone, 1 mM sodium pyruvate, 50 mg/l ascorbic acid, also with the 
addition of penicillin, streptomycin, and fungizone (Invitrogen, Carlsbad, CA). 
After allowing 24 h for cell attachment, constructs were removed from their 
cassettes and transferred into 24-well plates with 1 ml of medium and cultured 
under static conditions for 9, 15, and 21 days with serum-free chondrogenic 
medium either with or without the addition of 10 ng/ml TGF-~1 replenished every 
3 days. Eight samples were cultured for each scaffold group (PCl and 
PCLlECM) and growth factor treatment (-TGF and + TGF) for each culture time 
(9, 15, and 21 days), at the end of which samples were rinsed with PBS and 
stored for later analysis. Three samples were prepared for assessing construct 
cellularity and glycosaminoglycan content and synthetic activity, one sample was 
prepared for scanning electron microscopy, and four samples were prepared for 
assessing gene expression through real-time reverse transcription polymerase 
chain reaction. 
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Chondrogenic Differentiation Assays 
Samples for biochemical assays were digested in 500 ~L of a proteinase 
K solution while incubating in a 56°C water bath for 16 h. The proteinase K 
solution consisted of 1 mg/mL proteinase K, 0.01 mg/mL pepstatin A, and 0.185 
mg/mL iodoacetamide, in a tris-EDTA buffer made by dissolving 6.055 mg/mL 
tris(hydroxymethyl aminomethane) and 0.372 mg/mL EDTA with pH adjusted to 
7.6. DNA and matrix components were extracted via three repetitions of a freeze, 
thaw, and sonication cycle, where samples were frozen for 30 min at -80°C, 
thawed for 30 min at room temperature, and sonicated for 30 min in order to 
allow DNA and matrix components into the solution. 
Glycosaminoglycan content was determined by quantifying GAG using the 
colorimetric dimethylmethylene blue assay (Sigma-Aldrich, St. Louis, MO) and 
chondroitin sulfate standards as previously described [184]. Absorbance was 
measured on a plate reader (BioTek Powe rWave , Winooski, Vf). Resulting GAG 
measurements in ~g were determined for each sample. For glycosaminoglycan 
synthetic activity, the resulting GAG amounts were normalized to the amount of 
DNA for each sample. 
Cellularity was determined by quantifying double-stranded DNA using the 
fluorometric PicoGreen assay (Invitrogen, Carlsbad, CA) and DNA standards as 
previously described [184]. Fluorescence was measured on a plate reader 
(BioTek FL x800, Winooski, VT). Resulting DNA measurements in ~g were 
converted to cell numbers by correlating to DNA extracted from a known number 
of MSCs. 
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Scanning Electron Microscopy 
Samples for scanning electron microscopy were fixed in 2.5% 
glutaraldehyde, dehydrated through a graded series of ethanol from 70% to 
100%, air-dried overnight then mounted on aluminum stubs to visualize the top 
surface. Samples were sputter coated with gold for 1 min prior to imaging via 
SEM (FEI Quanta 400, Hillsboro, OR). 
Real-time RT-PCR 
Samples for real-time reverse transcription polymerase chain reaction 
were stored in RNAlater (Qiagen, Valencia, CA) at -20°C to stabilize and protect 
RNA. After all samples were collected, total RNA was extracted using the 
RNeasy mini kit (Qiagen, Valencia, CA) according to the manufacturer's 
instructions as previously described [168]. Constructs were placed in lysis buffer 
to lyse cells. After gentle mixing to allow RNA into the solution, the lysate was 
transferred to a QIAshredder column (Qiagen, Valencia, CA) for homogenization. 
An equal volume of 70% ethanol was added to the lysate and the mixture was 
transferred to an RNeasy mini spin column (Qiagen, Valencia, CA) where RNA 
was isolated and purified according to the manufacturer's animal cell protocol, 
with additional washes as previously described to improve the purity of total RNA 
[188]. Reverse transcription was then carried out to synthesize cDNA from 
purified RNA samples using Oligo(dT) primers (Promega, San Luis Obispo, CA) 
and SuperScript III reverse transcriptase (Invitrogen, Carlsbad, CA). Finally, 
cDNA was subjected to real-time PCR (Applied Biosystems 7300 Real-Time 
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PCR System, Foster City, CA) to quantify the gene expression of aggrecan, 
collagen type II, and collagen type I. 
Results were analyzed using the 2-MCt method to determine relative 
changes in target gene expression as compared to untreated controls [189). 
Target gene expression was first normalized to the expression of the 
housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) then 
converted to a fold ratio as compared to the baseline expression of that target 
gene measured in MSC controls taken directly after expansion just prior to 
seeding onto scaffolds. The sequences of primers used in this analysis are as 
follows: GAPDH: 5'-TCACCATCTTCCAGGAGCGA-3', 5'-
CACAA TGCCGAAGTGGTCGT-3'; aggrecan: 5'-
GCTACGGAGACAAGGATGAGTTC-3', 5'-CGT AAAAGACCTCACCCTCCAT -3'; 
collagen type II: 5'-AACACTGCCAACGTCCAGAT-3', 5'-
CTGCAGCACGGTATAGGTGA-3'; collagen type I: 5'-
ATGGATGAGGAAACTGGCAACT -3', 5'-GCCATCGACAAGAACAGTGTAAGT-
3'. 
Statistical Analysis 
Both characterization and chondrogenic differentiation studies were 
performed each with two separate and independent experiments. Although the 
trends were similar between experimental runs, the data presented here for both 
characterization and chondrogenic differentiation studies are derived from one 
experiment to mitigate potential differences between cell harvests. For each 
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experiment, cells from six rabbits were pooled together in effort to reduce 
variation between individual animals [187]. 
Characterization results for the glycosaminoglycan and collagen contents 
of cartilaginous extracellular matrix within PCLlECM constructs generated in flow 
perfusion culture, and subsequent PCUECM composite scaffolds obtained 
following decellularization, are reported as mean ± standard deviation for n = 3. A 
Student's t-test at a significance level of 5% was performed to determine whether 
the decellularization procedure (Construct vs. Scaffold) had a significant effect on 
glycosaminoglycan and collagen contents. 
Chondrogenic differentiation in static culture was assessed through 
biochemical assays to evaluate cellularity and glycosaminoglycan content and 
synthetic activity with n = 3 and quantitative gene expression of aggrecan, 
collagen type II, and collagen type I with n = 4. Results are reported as mean ± 
standard deviation. A three-factor ANOVA was first performed to determine 
significant global effects or interactions among scaffold group (PCl and 
PCLlECM), growth factor treatment (-TGF and + TGF), and culture time (9, 15, 
21 days). Multiple pairwise comparisons were then made using the Tukey 
procedure to determine significant differences. All statistical analyses were 
performed at a significance level of 5%. 
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Results 
PCUECM Cartilaginous Composite Characterization 
PCUECM constructs and PCUECM composite scaffolds were visualized 
to assess overall morphological appearance in response to the decellularization 
procedure. Bovine chondrocytes cultured on electrospun microfiber scaffolds 
under dynamic conditions in the flow perfusion bioreactor for 9 days to generate 
PCUECM constructs, are most prevalent at the top surface in scanning electron 
micrographs (Figure V-2A) , with some cells present within the construct seen 
through hematoxylin staining (Figure V-2B). Cartilaginous matrix is predominantly 
localized to the chondrocytes with a sparse distribution of Safranin 0 staining 
evident within the construct (Figure V-2C). Following the decellularization 
procedure to yield PCUECM composite scaffolds, which included three cycles of 
freeze and thaw, air-dry overnight, and sterilization via ethylene oxide exposure, 
chondrocytes are no longer apparent at the top surface in scanning electron 
micrographs (Figure V-20), as well as within the scaffold as seen through 
hematoxylin staining (Figure V-2E). A layer of cartilaginous matrix remains visible 
at the top surface of the scaffold in scanning electron micrographs (Figure V-20), 
while retaining a similar distribution within the scaffold as shown through Safranin 
o staining (Figure V-2F). 
Cartilaginous matrix composition in terms of glycosaminoglycan and 
collagen contents for PCUECM constructs and PCUECM composite scaffolds 
were characterized (Figure V-3). Although there is no significant difference in the 
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collagen content between constructs and scaffolds, constructs contain more 
glycosaminoglycan than scaffolds, indicating a reduction in glycosaminoglycan 
content in response to the decellularization procedure. 
Cellularity and Glycosaminoglycan 
PCLlECM composite scaffolds along with plain PCl control scaffolds were 
seeded with rabbit MSCs and cultured under static conditions for 9, 15, and 21 
days in serum-free medium with or without the addition of TGF-[31 to evaluate the 
chondrogenic properties of PCLlECM composite scaffolds. Table 1 summarizes 
the global effect of each experimental factor on the biochemical results. TGF-[31 
treatment had a significant effect on the glycosaminoglycan synthetic activity 
(GAG/DNA) of MSCs differentiating along the chondrogenic lineage but only on 
PCLlECM composite scaffolds. The presence of cartilaginous extracellular matrix 
on electrospun microfiber scaffolds had a significant effect on cellularity, 
glycosaminoglycan content (GAG), and GAG/DNA. 
Cellularity results showed that cell numbers were not statistically different 
between treatment groups at each time point, whether cells were cultured with or 
without TGF-[31 on PCl scaffolds or PCLlECM composite scaffolds (Figure V-
4A). Cellularity remained constant over time without TGF-[31 exposure, while all 
constructs treated with TGF-[31 exhibited a decrease in cellularity from 9 to 21 
days of culture. Glycosaminoglycan content remained constant over time for PCl 
constructs and was not statistically different between PCl constructs cultured 
with or without TGF-[31 (Figure V-4B). PCLlECM constructs contained more GAG 
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than PCL constructs at 9 days, with PCLlECM constructs cultured with TGF-~1 
containing the most GAG at 9 days. Though PCLlECM composite scaffolds 
started with an initial amount of GAG (7.45 ± 0.59 I-Ig) in addition to the amount of 
GAG inherent for the seeded cells (2.77 ± 0.73 I-Ig), a reduction in GAG was 
observed sooner at 9 days for cultures without TGF-~1 and later at 15 days for 
cultures with TGF-~1. Glycosaminoglycan synthetic activity remained constant 
over time for all treatment groups (Figure V-4C). Interestingly, although cells 
cultured on PCL scaffolds did not exhibit higher GAG/DNA in response to TGF-
~1 exposure, those cultured on PCLlECM composite scaffolds and treated TGF-
~1 did however demonstrate higher GAG/DNA at 9 and 21 days. 
Scanning electron micrographs were taken of the top surface of constructs 
to visualize the overall morphology throughout the culture period (Figure V-5). 
Though PCLlECM composite scaffolds started with an initial cartilaginous matrix 
while PCL scaffolds did not, MSCs did not visibly accumulate extracellular matrix 
over time on either scaffold. In contrast to constructs with chondrocytes where 
rounded cell bodies were well distinguished, MSCs were flat and spread forming 
a smooth coat over the construct surface. Those constructs treated with TGF-~1 
appeared to develop a striated texture with a rippled appearance after 21 days of 
culture. 
Quantitative Gene Expression 
Aggrecan, collagen type II, and collagen type I gene expression was 
measured by real-time reverse transcription polymerase chain reaction to assess 
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the chondrogenic properties PCUECM composite scaffolds. Table 2 summarizes 
the global effect of each experimental factor on the quantitative gene expression 
results. TGF-J31 had a significant effect on the expression of aggrecan, collagen 
type II, and collagen type I. The presence of cartilaginous extracellular matrix on 
electrospun microfiber scaffolds had a significant effect on the expression of 
collagen type I. 
Aggrecan gene expression was significantly higher for cells cultured with 
TGF-J31 and exhibited an increasing trend over time (Figure V-6A). In cultures 
without TGF-J31, aggrecan expression was not statistically different than MSCs at 
day 0 and remained constant from 9 to 21 days of culture, with no statistical 
difference between cells cultured on PCl scaffolds or PCUECM composite 
scaffolds. In cultures with TGF-J31 however, statistical differences in aggrecan 
expression compared to MSCs at day 0 were detected beginning at 9 days for 
PCUECM composite scaffolds and later at 15 days for PCl scaffolds. While cells 
cultured with TGF-J31 exhibited the highest levels of aggrecan expression at 21 
days, there was no statistical difference between cells cultured on PCl scaffolds 
(10.0 ± 2.7 fold) or PCUECM composite scaffolds (11.6 ± 3.8 fold). 
Similar to aggrecan gene expression, collagen type II gene expression 
was significantly higher for cells cultured with TGF-J31 and exhibited an 
increasing trend over time (Figure V-68). In cultures without TGF-J31, collagen 
type II expression was not statistically different than MSCs at day 0 and 
remained constant from 9 to 21 days of culture, with no statistical difference 
between cells cultured on PCl scaffolds or PCUECM composite scaffolds. In 
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cultures with TGF-j31, statistical differences in collagen type II expression 
compared to MSCs at day 0 were detected beginning at 15 days for both PCl 
scaffolds and PCLlECM composite scaffolds. While cells cultured with TGF-j31 
exhibited the highest levels of collagen type II expression at 21 days, there was 
no statistical difference between cells cultured on PCl scaffolds (629.3 ± 135.6 
fold) or PCUECM composite scaffolds (668.4 ± 317.7 fold). 
In contrast to aggrecan and collagen type II gene expression, collagen 
type I gene expression was significantly lower for cells cultured with TGF-j31 and 
remained constant over time, with no statistical difference between cells cultured 
on PCl scaffolds or PCLlECM composite scaffolds (Figure V-6C). In cultures 
without TGF-j31, collagen type I expression increased over time and was the 
highest for cells cultured on PCl scaffolds at 15 and 21 days (6.9 ± 1.0 fold and 
9.0 ± 1.1 fold), while cells cultured on PCUECM composite scaffolds on the other 
hand, demonstrated significantly lower collagen type I expression (4.5 ± 1.5 fold 
and 5.8 ± 0.8 fold). Furthermore, the level of collagen type I expression for cells 
cultured on PCUECM composite scaffolds was comparable to the expression 
observed with TGF-j31 treatment. 
Discussion 
The objective of this study was to fabricate PCLlECM composite scaffolds 
consisting of electrospun microfibers coated with cartilaginous extracellular 
matrix, and evaluate their ability to support the chondrogenic differentiation of 
MSCs in vitro. This study was designed to investigate the fabrication of 
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PCUECM composite scaffolds through dynamic culture of bovine chondrocytes 
in a flow perfusion bioreactor, and to determine how the decellularization 
procedure affects matrix morphology and composition. PCUECM composite 
scaffolds where evaluated for their ability to support the chondrogenic 
differentiation of rabbit MSCs in vitro induced by TGF-~1 exposure, and to 
determine whether the presence of cartilaginous matrix would further enhance 
this differentiation response by providing cells with a more biological 
microenvironment compared to plain PCl scaffolds. 
Culturing chondrocytes under direct flow perfusion conditions providing a 
low level of fluid shear stress has been shown to stimulate proliferation and 
accumulation of glycosaminoglycan and collagen [118, 166, 190, 191]. Thus in 
this study, dynamic culture in a flow perfusion bioreactor was employed to 
generate PCUECM constructs. With our electrospun microfiber scaffolds and the 
chosen flow rate, we observed that bovine chondrocytes deposited cartilaginous 
extracellular matrix predominately localized to their pericellular space with a 
sparse distribution of matrix throughout the thickness of the constructs. Although 
with our present scaffold geometry and culture parameters, cartilaginous matrix 
was not very well distributed throughout the depth of our constructs, the optimal 
combination of seeding density, flow rate, and pore size may be further 
investigated to balance cell retention and matrix distribution throughout the 
constructs. 
From scanning electron micrographs and histological sections, it appears 
that chondrocytes may have proliferated quickly to occlude the surface porosity 
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of the electrospun microfiber scaffolds, and thus resulted in a large amount of 
cartilaginous matrix at the surface of the constructs, consisting of 
glycosaminoglycan and collagen. In decellularizing PCLlECM constructs to yield 
PCLlECM composite scaffolds, we observed a decrease in glycosaminoglycan 
content with collagen content unaffected. Safranin 0 staining revealed that the 
reduction in glycosaminoglycan is likely associated with the chondrocytes 
removed from the surface of the constructs via the decellularization procedure. 
However, since cartilaginous matrix was visibly present in PCLlECM composite 
scaffolds, and due to the amount of glycosaminoglycan and collagen detected 
through biochemical assays, we sought to evaluate PCLlECM composite 
scaffolds for their ability to support the chondrogenic differentiation of MSCs in 
vitro. 
PCLlECM composite scaffolds along with plain PCl control scaffolds were 
seeded with rabbit MSCs and cultured in serum-free medium either with our 
without the addition of TGF-~1. Serum-free culture was applied in this study in 
order to strictly investigate the effects of physical matrix interactions and 
biochemical signaling on chondrogenic differentiation. Although serum-free 
culture is beneficial for studying chondrogenic differentiation in a controlled 
manner in vitro, serum deprivation has been shown to affect cell attachment and 
inhibit proliferation [192]. As such, we observed a decrease in cellularity for cells 
cultured on both PCl scaffolds and PCLlECM composite scaffolds driven toward 
chondrogenic differentiation through TGF-~1 exposure. 
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Our results demonstrated that while MSCs did not accumulate a 
detectable amount of glycosaminoglycan over time, culturing MSCs on both PCl 
scaffolds and PCLlECM composite scaffolds with TGF-f31 significantly enhanced 
chondrogenic differentiation, as seen in the up-regulation of aggrecan and 
collagen type II gene expression over time relative to the baseline expression of 
MSCs at day O. This differentiation response is further supported by the minimal 
collagen type I expression throughout the 21 days of culture, where collagen type 
I expression indicates pre-chondrogenic undifferentiated MSCs or a fibroblastic 
phenotype [193]. As previously shown with electrospun PCl nanofiber scaffolds 
(average fiber size 500 to 700 nm) [102, 103], we prove here that microfiber 
scaffolds (average fiber size 10 !-1m) also support MSC chondrogenesis induced 
by TGF-f31. Additionally, we demonstrate that PCLlECM composite scaffolds, 
containing cartilaginous matrix generated by chondrocytes, are also capable of 
supporting the chondrogenic differentiation of MSCs in vitro. 
While the presence of cartilaginous matrix did not seem to enhance 
chondrogenic gene expression beyond the levels seen with TGF-f31 exposure, it 
did however promote an up-regulation in aggrecan expression sooner than plain 
scaffolds without cartilaginous matrix. Furthermore, cells cultured on composite 
scaffolds containing cartilaginous matrix exhibited significantly lower collagen 
type I expression comparable to the minimal levels seen with TGF-f31 treatment. 
Therefore, the presence of cartilaginous matrix alone without the addition of 
growth factors may provide biological signals to reduce the fibroblastic phenotype 
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of differentiating MSCs as marked in the collagen type I expression levels 
observed for cells cultured on PCLlECM composite scaffolds. 
The up-regulation in aggrecan gene expression in response to TGF-131 
treatment did not translate to an increase in glycosaminoglycan content in the 
constructs. Given that both GAG content and GAG/DNA levels remained 
constant over time, it is likely that the soluble proteoglycans produced by 
differentiating cells were not incorporated into the constructs but rather released 
into the medium, which has been reported in other studies with both 
chondrocytes and stem cells cultured on polymer scaffolds [194, 195]. Thus, the 
absence of glycosaminoglycan accumulation may be attributed to the controlled 
in vitro culture conditions and regular medium changes. Although different 
outcomes may be likely under physiological conditions in vivo, assessment of 
chondrogenesis in vivo was beyond the scope of this present study. 
PCLlECM composite scaffolds contained an initial cartilaginous matrix 
deposited by chondrocytes in flow perfusion culture. Since the cartilaginous 
matrix was not crosslinked or physically conjugated to the polymer scaffolds, we 
observed a reduction in GAG content particularly within the first two weeks of 
culture, where proteoglycans may be leaching into the aqueous environment; 
similar to what has been observed with cartilage explants in culture [196, 197]. 
Interestingly, we found that PCLlECM constructs cultured with TGF-131 retained a 
higher amount of GAG in the first week of culture than those cultured without 
TGF-131. Thus, the combination of cartilaginous matrix and growth factor 
treatment promotes the retention of GAG either originally present in PCLlECM 
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composite scaffolds or produced by the cultured cells. Furthermore, we 
discovered that only when cells where cultured in the presence of cartilaginous 
matrix in PCLlECM composite scaffolds, did TGF-~1 treatment result in higher 
GAG/DNA. Therefore, it appears that cartilaginous matrix facilitates 
chondrogenesis by enhancing the effects of TGF-~1 in vitro. 
The cartilaginous matrix deposited by chondrocytes in fabricating 
PCLlECM composite scaffolds proved to be too dense for MSCs to remodel and 
penetrate under static culture conditions, as confirmed through histology (data 
not shown). While specific cell-matrix interactions are important in regulating the 
initial attachment of MSCs, the lack of cell penetration through the dense layer of 
cartilaginous matrix at the surface of PCLlECM composite scaffolds limits their 
spatial contact with extracellular matrix proteins to essentially two-dimensions. 
Thus in this study, although a complex set of matrix molecules were presented, 
the full potential of these biological signals to guide chondrogenic differentiation 
might not be experienced by cells in three-dimensions. 
Though the porous nature of sponge-like scaffolds fabricated using native 
cartilage components facilitate cell seeding, hence promoting three-dimensional 
interactions [181, 182], the precise mechanisms leading to chondrogenesis are 
unclear. That is, since the entire scaffold structure is comprised of matrix 
proteins, it is difficult to distinguish whether MSC chondrogenic differentiation is 
simply due to maintaining cells in a three-dimensional geometry, or whether 
chondrogenesis is particularly attributed to specific cell-matrix interactions with 
biological signals in the matrix. Alternatively, the composite nature of our 
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PCLlECM scaffolds, with a porous fiber mesh structure as the base material, 
makes it possible to examine the underlying mechanisms of chondrogenesis; as 
in this study where we observed that the presence of cartilaginous matrix in 
PCLlECM composite scaffolds in fact augmented the effect of growth factor 
treatment otherwise not seen for plain PCl controls. By tailoring scaffold 
properties through controllable electrospinning parameters, together with 
adjusting the morphology and composition of cartilaginous matrix in varying the 
conditions of chondrocyte seeding and culture, we may be able to engineer 
PCLlECM composite scaffolds with sufficient porosity to support chondrogenesis. 
Maintaining adequate porosity to facilitate subsequent cell seeding and infiltration 
would allow us to investigate MSC chondrogenic differentiation in a purely 
structural three-dimensional environment (PCl), or in an instructive cartilaginous 
microenvironment containing complex arrays of biological signals (PCLlECM), to 
gain a better understanding of the mechanisms regulating chondrogenesis. 
In this study we utilized a xenogenic source of chondrocytes to generate 
cartilaginous matrix in fabricating PCLlECM composite scaffolds. While limited 
research has been done to explore the potential inductive properties of 
xenogenic cartilaginous matrix, xenogenic osteochondral grafts decellularized 
through a photooxidation technique have been shown to repair cartilage defects 
with no adverse immune response [198]. Also, acellular bovine cartilage matrix 
molded through freeze-drying and crosslinked via ultraviolet irradiation, showed 
good biocompatibility with rabbit MSCs and no cytotoxic effects in both direct 
contact and extraction assays [199]. Chondrocytes can be stimulated to deposit 
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large amounts of cartilaginous matrix under engineered culture conditions as 
demonstrated with the fabrication of PCLlECM composite scaffolds in this study. 
Due to the limitations and drawbacks with autogenic or allogenic chondrocyte 
harvest, xenogenic chondrocytes are a potentially clinically applicable cell source 
in generating acellular cartilaginous scaffolds to guide cartilage repair, provided 
that the decellularization procedure effectively removes cellular components 
[200]. 
Conclusion 
In this work, we fabricated PCLlECM composite scaffolds consisting of 
electrospun microfibers coated with cartilaginous extracellular matrix, and 
evaluated their ability to support the chondrogenic differentiation of MSCs in vitro. 
PCLlECM composite scaffolds supported chondrogenic differentiation induced by 
TGF-j31 exposure, as evidenced in the up-regulation of aggrecan and collagen 
type II gene expression. The presence of xenogenic cartilaginous matrix alone 
reduced collagen type I gene expression to levels comparable to those observed 
with TGF-j31 treatment. Cartilaginous matrix further enhanced the effects of 
growth factor treatment as evidenced in the higher glycosaminoglycan synthetic 
activity for cells cultured on PCLlECM composite scaffolds with TGF-j31, whereas 
TGF-j31 treatment alone did not translate to higher GAG/DNA levels for cells 
cultured on plain PCl scaffolds. The present study demonstrated the fabrication 
of polymer/extracellular matrix composite scaffolds using a flow perfusion 
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bioreactor to incorporate biological signals in a synthetic scaffolding system for 
cartilage tissue engineering applications. 
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Figure V-1: Schematic representation of the overall experimental design. 
PCl/ECM constructs were generated through flow perfusion culture of bovine 
chondrocytes, then decellularized and characterized for matrix morphology and 
composition in response to the decellularization procedure. PCl/ECM composite 
scaffolds along with plain PCl polymer scaffolds were seeded with rabbit MSCs 
and evaluated for their ability to support chondrogenic differentiation in static 
culture with or without the addition of TGF-~1 . 
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SEM Hematoxylin Safranin 0 
Figure V-2: Morphology of PCL/ECM constructs generated through flow 
perfusion culture of bovine chondrocytes (A-C) and PCL/ECM composite 
scaffolds obtained following decellularization (D-F). Images show scanning 
electron micrographs illustrating surface characteristics (A & D), histological 
sections stained with hematoxylin to visualize cells (8 & E), and histological 
sections stained with Safranin 0 to visualize cartilaginous matrix (C & F). The 
scale bar represents 100 IJm for all images. 
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Figure V-3: Composition of PCL/ECM constructs generated through flow 
perfusion culture of bovine chondrocytes and PCL/ECM composite scaffolds 
obtained following decellularization. Plots show glycosaminoglycan and collagen 
contents as mean ± standard deviation for n = 3 from one experiment, although 
similar trends were observed in two independent experiments. Significant 
difference (p < 0.05) between treatments is noted with (*). 
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Figure V-4: Biochemical results for MSes cultured on plain polymer scaffolds 
(pel) and composite scaffolds (pel/EeM) either with (+) or without (-) the 
addition of TGF-r31. Plots show cellularity (A), glycosaminoglycan content (B) , 
and glycosaminoglycan synthetic activity (e), as mean ± standard deviation for n 
= 3 from one experiment, although similar trends were observed in two 
independent experiments. Within a specific treatment group, significant 
difference (p < 0.05) between time points is noted with (#). At a specific time 
point for each scaffold group, signif icant difference (p < 0.05) compared to - TGF-
r3 1 controls is noted with (*) . At a specific time point for each growth factor 
treatment group, significant difference (p < 0.05) compared to pel controls is 
noted with (**). 
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Figure V-S: Representative scanning electron micrographs of the top surface of 
plain polymer scaffolds (PCl) and composite scaffolds (PCl/ECM) seeded with 
MSCs and cultured either with (+) or without (-) the addition of TGF-~1. For each 
treatment group, three rows of images are shown for constructs after (A) 9 days 
of culture, (8) 15 days of culture, and (C) 21 days of culture. The scale bar 
represents 1 00 ~m for all images. 
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Figure V-6: Quantitative gene expression results for MSes cultured on plain 
polymer scaffolds (pel) and composite scaffolds (pel/EeM) either with (+) or 
without (-) the addition of TGF-~1. Plots show aggrecan expression (A), collagen 
type II expression with the inset on a rescaled axis (8), and collagen type I 
expression (e). Data are presented as fold ratio after being normalized to the 
expression of GAPDH. Fold ratios are shown as mean ± standard deviation for n 
= 4 from one experiment, although similar trends were observed in two 
independent experiments. Significant difference (p < 0.05) compared to the gene 
expression of MSes at day 0 is noted with (t). Within a specific treatment group, 
significant difference (p < 0.05) between time points is noted with (#). At a 
specific time point for each scaffold group, significant difference (p < 0.05) 
compared to - TGF-~1 controls is noted with (*). At a specific time point for each 
growth factor treatment group, significant difference (p < 0.05) compared to pel 
controls is noted with (**). 
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Table V-1. Global effect of experimental factors on biochemical results. 
Significance levels were determined using a three-factor ANOVA and the Tukey 
procedure. Not significant is abbreviated as NS. 
Factor Comparison Cellularity GAG GAG/DNA 
- TGF-~1 vs. + TGF-~1 NS NS P < 0.05 
PCl vs. PCUECM p < 0.05 P < 0.05 P < 0.05 
Day 9 vs. Day 15 p < 0.05 P < 0.05 NS 
Day 9 vs. Day 21 p < 0.05 P < 0.05 NS 
Day 15 vs. Day 21 p < 0.05 NS NS 
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Table V-2. Global effect of experimental factors on quantitative gene expression 
results. Significance levels were determined using a three-factor ANOVA and the 
Tukey procedure. Not significant is abbreviated as NS. 
Factor Comparison Aggrecan Collagen Type II Collagen Type I 
- TGF-~1 vs. + TGF-~1 P < 0.05 P < 0.05 P < 0.05 
PCl vs. PCLlECM NS NS P < 0.05 
Day 0 vs. Day 9 p < 0.05 NS P < 0.05 
Day 0 vs. Day 15 p < 0.05 P < 0.05 P < 0.05 
Day 0 vs. Day 21 p < 0.05 P < 0.05 p < 0.05 
Day 9 vs. Day 15 NS P < 0.05 p < 0.05 
Day 9 vs. Day 21 p < 0.05 P < 0.05 P < 0.05 
Day 15 vs. Day 21 p < 0.05 P < 0.05 NS 
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CHAPTER VI 
CONCLUDING REMARKS 
Biomaterial scaffolds for osteochondral tissue engineering must not only 
act as a template for tissue growth, but also as instructive microenvironments to 
guide cellular function. Since mesenchymal stem cells (MSCs) playa vital role in 
the natural development, maintenance, and repair of cartilage and bone, and are 
influenced by factors in the native tissue microenvironment, scaffolds for 
osteochondral regeneration should contain appropriate signals to guide MSC 
differentiation. This thesis work explored interactions that modulate MSC 
chondrogenic and osteogenic differentiation in an effort to develop 
polymer/extracellular matrix (PCLlECM) composite scaffolds to facilitate 
osteochondral tissue regeneration. 
In an osteochondral defect, interactions exist between bone marrow cell 
populations within the adjacent bone marrow niche. Since the role of 
hematopoietic stem and progenitor cells (HSPCs) in regulating the osteogenic 
differentiation of MSCs is not well understood, the first part of this thesis explored 
the interaction between HSPCs and MSCs in direct contact co-culture. Results 
showed that HSPCs played an active role in modulating the development and 
maintenance of the osteogenic niche. Although this investigation was performed 
in two-dimensional culture to specifically examine cellular interactions that might 
take place on bone surfaces, three-dimensional culture using electrospun 
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microfiber scaffolds could serve as a model for the more porous niche in 
trabecular bone. Additionally, the incorporation of an initial mineralized matrix 
could provide insight into how HSPCs regulate bone remodeling for a broader 
view on the role of HSPCs in bone regeneration. 
The second part of this thesis focused on fabricating composite scaffolds 
consisting of poIY(E-caprolactone) (PCL) microfibers coated with mineralized 
extracellular matrix (ECM). Studies in our laboratory using a titanium fiber mesh 
base material with a mineralized matrix coating have shown promising results, 
and thus warranted the transition to a biodegradable scaffolding system. 
Mineralized PCLlECM composite scaffolds were fabricated with different matrix 
maturity and composition via flow perfusion culture. Results showed that 
mineralized matrix was capable of inducing osteogenic differentiation even in the 
absence of dexamethasone, with a more rapid and robust differentiation 
response elicited by a more mature matrix containing higher quantities of 
collagen and minerals. This investigation was very promising in that osteoblastic 
differentiation was achieved in vitro through specific interactions with the 
scaffolding material, without the need for external factors such as physical 
stimulation via bioreactor culture, or soluble signaling including growth factors 
and dexamethasone. Although this analysis demonstrated how matrix signals 
modulate osteogenic differentiation while focusing on the osteoinductive ability of 
the scaffold itself, the bioactive components within the scaffold include more than 
collagen and minerals, and thus should be further characterized to determine the 
precise osteoinductive mechanisms. Even though this biodegradable scaffolding 
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system demonstrated osteoconductivity and osteoinductivity in vitro, application 
of this scaffold in vivo would allow more direct evaluation of its potential to 
enhance bone regeneration, with specific interest in its ability to recruit host 
progenitor cells and degradation in the physiological environment. 
Along with the concept of imparting bioactive properties to an otherwise 
inert scaffold, the third part of this thesis explored the fabrication of cartilaginous 
PCLlECM composite scaffolds. Results showed that although some 
glycosaminoglycan content was lost during scaffold processing, the remaining 
cartilaginous matrix served to reduce fibroblastic phenotype and further promoted 
chondrogenesis in combination with TGF-J31. While cartilaginous scaffolds did 
not result in an overwhelming inductive effect as was observed with mineralized 
scaffolds, mechanisms governing chondrogenic induction may rely more on 
soluble signals and precise three-dimensional interactions. Further optimization 
of cartilaginous scaffolds might include varying fabrication parameters to obtain a 
more uniform cartilaginous matrix coating, and adjusting processing methods to 
better preserve sensitive matrix components. Flow perfusion culture could 
increase cellular contact with matrix components for testing, though isolating true 
scaffold effects in vitro remains a challenge and thus, must be addressed in an in 
vivo environment where functional capabilities can be evaluated. 
In conclusion, while further investigation is necessary to optimize and test 
these scaffolds to induce the regeneration of cartilage and bone, this work 
demonstrates the importance of harnessing signals present in the native 
microenvironment to modulate chondrogenic and osteogenic differentiation. 
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